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1. Introduction 
1.1. Regulation of the Circulatory System 
 Relevance of Resistance Arteries 
Small arteries or arterioles with a diameter smaller than 400 μm constitute the main 
flow resistance in the vascular system and are therefore characterized as arterial 
resistance vessels (Intengan and Schiffrin (2000)). They reduce the blood pressure 
and the blood flow in capillaries to ensure the possibility of gas and nutrient exchange. 
A blood pressure of about 35 mmHg and a blood flow of about 0.03 cm/sec prove to 
be a good setting for gas and nutrient exchange between the capillaries and the 
surrounding tissue.  
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Figure 1 “Changes in blood pressure, velocity, and the area of the arteries, capillaries, 
and veins of the circulatory system” 
(http://www2.estrellamountain.edu/faculty/farabee/BIOBK/BioBookcircSYS.html, last 
accessed May 25th 2015) 
Velocity and blood pressure are high, while the total area is small in both large and small 
arteries as seen on the left side of the graph. Due to Ohm’s law and the Hagen-Poiseuille 
equation there is a decrease in blood pressure as soon as there is an increase in vascular 
resistance, which is inversely dependent on the 4th power of the vessel’s radius, thereby 
explaining the decrease of blood pressure in arterioles and capillaries compared to larger 
arteries. The reduction of blood velocity in arterioles and capillaries is explained by the 
continuity equation, which describes the relation between velocity and total area (cross section) 
of all blood vessels. As this relation is constant, the increase in cross section of all small blood 
vessels leads to a decrease in velocity. As per Kirchhoff’s 2nd law, the inverse of the total vessel 
resistance of one vascular bed is equal to the sum of the individual inverse artery’s resistance 
(see below). 
(Hick and Hick (2013), chapter 4.2.2.1; Pape, Kurtz et al. (2014), chapter 6.4) 
 
Ohm’s law describes the relationship between blood vessel resistance, blood pressure 
and blood flow. 
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𝑅 =  
𝛥𝑃
𝐼
 
 
R Vascular resistance 
ΔP Difference in blood pressure along the blood vessel 
I Blood flow  
 
The Hagen-Poiseuille equation, which Gotthilf Heinrich Ludwig Hagen and Jean 
Léonard Marie Poiseuille discovered independently of each other, describes the 
relationship between vascular resistance and blood viscosity, vessel diameter and 
vessel length. For physiological analysis this equation therefore allows a more 
detailed analysis of vascular resistance than Ohm’s law. 
 
𝑅 =  
8 ∗  𝜂 ∗ 𝑙
𝑟4 ∗  𝜋
 
 
R Vascular resistance 
η Blood viscosity 
l Length of the blood vessel 
r Radius of the blood vessel 
π Mathematical constant  
 
Since blood viscosity only changes slowly and slightly due to a change of the 
hematocrit and the vessel length usually stays the same, the vessel diameter is the 
only parameter that can be changed quickly to adjust vascular resistance.  
As it can be seen in the Hagen-Poiseuille equation above, the resistance is inversely 
proportional to the fourth power of the radius (r4), which explains the importance of 
small arteries in adjusting vascular resistance. The equation requires laminar and 
constant flow, long straight tubes with a circular diameter and a Newtonian fluid. Even 
if some of these factors are not fulfilled in blood vessels, the equation is important in 
understanding the concept of vascular resistance and the influence of the changing 
vessel diameter.  
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The continuity equation explains the reduction of the blood flow velocity caused by the 
increase in total cross-section of the capillaries.  
 
𝐴 ∗ 𝑣 = 𝑐𝑜𝑛𝑠𝑡. 
Or 
𝐴1 ∗  𝑣1 =  𝐴2 ∗  𝑣2 
 
A Cross section of all blood vessels 
v Blood velocity 
Kirchhoff’s 2nd law describes the relationship between the total resistance of a parallel 
vascular bed and the sum of the single artery‘s resistance. The inverse of the total 
vessel resistance of one vascular bed is equal to the sum of the individual inverse 
artery’s resistance. This means that the total resistance of a parallel vascular bed is 
always smaller than the smallest single artery’s resistance. 
 
1
𝑅𝑡𝑜𝑡𝑎𝑙
=
1
𝑅1
+
1
𝑅2
+
1
𝑅3
+ ⋯
1
𝑅𝑛
 
 
Rtotal Vascular resistance of all arteries of a vascular bed 
R1/2/3/…n Vascular resistance of singular arteries of a vascular bed 
(Hick and Hick (2013), chapter 4.2.2.1; Pape, Kurtz et al. (2014), chapter 6.4) 
 Regulation of Vascular Tone 
Vasoconstriction and vasodilation are the only parameters for rapidly adjusting 
vascular resistance and consequently vascular tone1. There are two mechanisms for 
regulating vascular tone, the first being calcium-dependent and the second calcium-
independent. The calcium-dependent regulation of vascular tone (i.e. smooth muscle 
tone) occurs either via receptors or depolarization/hyperpolarization, while the 
calcium-independent regulation occurs via the myosin-light chain kinase (MLCK) and 
the myosin-light chain phosphatase (MLCP), which phosphorylate and 
dephosphorylate the myosin-light chain (MLC) independently of the intracellular 
                                            
1 Vascular tone: “degree of constriction experienced by a blood vessel relative to its 
maximal dilated state” (http://www.cvphysiology.com/Blood%20Flow/BF002.htm; last 
accessed July 20th 2015) 
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calcium levels. Phosphorylation of the MLC leads to vasoconstriction, while 
dephosphorylation induces vasodilation.  
 Calcium-Dependent Regulation 
Calcium-dependent vasoconstriction increases intracellular calcium by releasing 
calcium from cytosolic stores, like the sarcoendoplasmic reticulum (SERCA), and by 
increasing the influx from the extracellular space through ligand-gated or voltage-
gated calcium channels. 
Depolarization opens voltage-dependent calcium channels (VDCCs), mainly L-type 
Ca2+ channels, to increase intracellular calcium and to induce constriction, while the 
receptor mediated constriction works via the G-Protein/PLC/DAG and IP3 cascade. IP3 
releases calcium from the sarcoplasmic reticulum and thus increases the cytosolic 
calcium, while DAG has several target proteins and can amongst others boost 
constriction by activating L-type Ca2+ channels and thus increase the intracellular 
calcium concentration (Webb (2003)). 
The normal cytosolic calcium concentration in relaxed smooth muscle cells is 
10-7 mol/l. As soon as intracellular calcium levels increase to 10-5 mol/l, up to four 
calcium ions can attach to and activate the calcium sensor calmodulin (CaM) (Teo and 
Wang (1973); Adelstein and Eisenberg (1980)). The myosin light-chain kinase (MLCK) 
is activated by an activated calmodulin (Dabrowska, Sherry et al. (1978); Adelstein 
and Eisenberg (1980)). MLCK in turn phosphorylates and thus activates the myosin 
light-chain (MLC), which enables the cross-bridging of myosin and actin and results in 
vasoconstriction (Dabrowska, Aromatorio et al. (1977)).  
 Calcium-Independent Regulation 
For a long time, calcium-dependent regulation of vascular tone was thought to be the 
only mechanism that could induce vasoconstriction until additional pathways were 
discovered that could evoke vasoconstriction without a change in intracellular calcium 
levels, but by directly regulating the MLCP and the MLCK.  
MLCP is predominantly inhibited by two pathways, the RhoA/ROCK/MYPT1 and the 
PLCβ/PKC/CPI-17 pathway (Mizuno, Isotani et al. (2008); Kitazawa, Eto et al. (2000)). 
Since these pathways lead to vasoconstriction without increasing the intracellular 
calcium levels, this induced calcium-independent vasoconstriction is often called 
calcium sensitization. RhoA is a small GTPase-protein that activates ROCK, which in 
turn phosphorylates the MYPT1 protein that is also called the myosin-binding subunit 
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(MBS) of the myosin phosphatase. The phosphorylation of the MYPT1 inhibits MLCP 
action. (Kimura, Ito et al. (1996)) 
The PLCβ/PKC/CPI-17 pathway also works via phosphorylation of its target protein, 
CPI-17, which is only expressed in smooth muscle cells and blocks the action of the 
MLCP when phosphorylated. There is a connection between both pathways as CPI-17 
is also activated via ROCK. (Eto, Kitazawa et al. (2001)) 
In addition to these inhibiting pathways, the MLCP is activated by NO via cGMP, 
which consequently induces calcium desensitization (Bolz, Vogel et al. (2003)). 
Calcium desensitization can however also be achieved by directly inhibiting the MLCK 
via phosphorylation by a kinase, such as the AMPK (Horman, Morel et al. (2008)). 
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Figure 2: Mechanisms of vasoconstriction and vasodilation in smooth muscle cells 
Vasoconstriction and vasodilation are influenced by calcium-dependent and calcium-
independent pathways. The balance of the activities of the MLCK and MLCP is important, as an 
increase in one will lead to phosphorylation (MLCK) or dephosphorylation (MLCP) of the MLC. 
When intracellular calcium levels increase, a calcium calmodulin complex is formed which 
activates the MLCK. This induces calcium-dependent vasoconstriction. However, there is also a 
calcium independent-mechanism to induce or enhance vasoconstriction. Via the 
RhoA/ROCK/MYPT1 and PLCβ/PKC/CPI-17 pathways the MLCP is blocked and 
dephosphorylation of the MLC is inhibited. This is called calcium-sensitization. When the MLCP 
is activated by PKG, vasodilation is induced, which is equivalent to calcium-desensitization. 
1.2. AMP-Kinase 
 Discovery and Structure of the AMP-Kinase 
Reactions catalyzed by the AMP-kinase were first described in 1973, inhibiting both 
the HMG-CoA reductase and the acetyl-CoA carboxylase, which are important 
enzymes in the synthesis of cholesterol and fatty acids (Hardie, Carling et al. (1998)). 
Both the HMG-CoA reductase kinase and the acetyl-CoA carboxylase kinase are 
found to be activated by an increase in the AMP/ATP ratio (Ferrer, Caelles et al. 
(1985); Yeh, Lee et al. (1980)). Further experiments led to the conclusion that these 
two kinases were indeed the same and it was then named „AMP-activated protein 
kinase“ (Carling, Zammit et al. (1987); Munday, Campbell et al. (1988); Sim and 
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Hardie (1988); Hardie and Carling (1997)). Today the AMP-kinase is a well-known 
enzyme regulating not only sterol or fatty acid synthesis but also energy homeostasis 
and is being referred to as a cellular “fuel gauge” (Hardie and Carling (1997)).  
The AMP-kinase is a heterotrimeric serine/threonine kinase consisting of three 
subunits, one catalytic α subunit and two regulatory subunits, the β and γ subunit 
(Mitchelhill, Stapleton et al. (1994); Stapleton, Gao et al. (1994)). There are two 
isoforms of the α and of the β subunit (α1 and α2; β1 and β2) and three isoforms of the 
γ subunit (γ1, γ2 and γ3) (Stapleton, Mitchelhill et al. (1996); Thornton, Snowden et al. 
(1998); Cheung, Salt et al. (2000)). The genes encoding for the AMPK subunits and 
isoforms are the PRKA genes (Hardie (2007)). Latest DNA sequencing technology 
has shown that the PRKA genes are universally existent in all eukaryotic cells, except 
a few parasites (Hardie 2018). 
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 Relevance of the AMP-Kinase 
 
Figure 3: The far-reaching influence of the AMP-kinase and how it self-regulates 
(Illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com)) 
As can be seen in Figure 3, the AMP-kinase influences a huge variety of pathways. It 
is an important enzyme for energy homeostasis as it influences these pathways to 
switch to an energy saving mode. By phosphorylating both HMG-CoA reductase and 
acetyl-CoA carboxylase the AMP-kinase inhibits both sterol and fatty acid synthesis, 
processes requiring ATP, and it even induces ATP producing pathways (e.g. fatty acid 
oxidation and glycolysis). Being activated by an anabolic increase in AMP, the AMP-
kinase induces catabolic pathways to conserve ATP, which led to it being named the 
“fuel gauge of the mammalian cell” (Hardie and Carling (1997)). 
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 Influence of the AMP-Kinase on Vascular Tone 
The AMP-kinase was also shown to influence vascular tone via Ca2+-dependent and 
independent pathways explained in sections 1.1.2.1 Calcium-Dependent Regulation 
and 1.1.2.2 Calcium-Independent Regulation.  
It has been reported that the AMP-kinase inhibits the RhoA/Rock/MYPT1 pathway via 
two mechanisms. The first mechanism is the phosphorylation of serine of p190-GAP, 
which binds and inhibits RhoA while the second mechanism is direct phosphorylation 
of RhoA on Ser188. The AMP-kinase thus activates the MLCP and consequently 
induces Ca2+-independent vasodilation. (Wang, Liang et al. (2011); Gayard, Guilluy et 
al. (2011)) The AMP-kinase has also been shown to inactivate the MLCK by 
phosphorylation of the CaM binding site at Ser815 inducing a vasodilation (Horman, 
Morel et al. (2008)). Furthermore, it can affect the actin cytoskeleton by 
depolymerizing the F-actin, thus affecting another pathway inducing Ca2+-independent 
vasodilation (Schubert, Qiu et al. 2017). 
In addition the AMP-kinase is now also known to influence calcium decreasing 
mechanisms by BkCa-channel mediated membrane hyperpolarization and by 
indirectly activating the SERCA (Schneider, Schubert et al. (2015)).  
The AMP-kinase does, however, not only regulate vascular tone by influencing 
smooth muscle cell contractility but has also been reported to play an important role in 
the endothelial regulation of vascular tone. It is considered to not only induce 
vasodilation by influencing the endothelium-dependent hyperpolarization (EDH) but 
also by phosphorylating the eNOS leading to an increased production of NO 
(Enkhjargal, Godo et al. (2014); Chen, Mitchelhill et al. (1999); Chen, Peng et al. 
(2009)).  
 Pathophysiological Relevance of the AMP-Kinase  
Not only the metabolic pathways like sterol and fatty acid synthesis and 
gluconeogenesis, but also vascular functions are deeply impaired in the metabolic 
syndrome. As the AMP-kinase has favorable effects on patients affected by the 
metabolic syndrome by improving insulin resistance and regulating hypertension, it is 
seen as a new possibility not only in the treatment of the metabolic syndrome but also 
of cardiovascular diseases especially when they are related to the metabolic 
syndrome (Fogarty and Hardie (2009); Wang, Liang et al. (2011); Cao, Luo et al. 
(2014); Dong, Zhang et al. (2010); Wang, Zhang et al. (2010)). This is also supported 
by evidence showing that the well-known anti-diabetic drug Metformin can, in addition 
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to AMP-kinase independent anti-diabetic mechanisms, activate the AMP-kinase and 
thus increases hepatic insulin sensitivity (Zhou, Myers et al. (2001); (Rena, Hardie et 
al. 2017)). 
Both catalytic AMPK α subunits have a different influence on the AMP-kinase’s 
metabolic effects. When mice globally lack the AMP-kinase’s α2 subunit, not only do 
they present with an elevated blood pressure, but also glucose intolerance and insulin 
resistance (Wang, Liang et al. (2011); Viollet, Andreelli et al. (2003)). The global α1 
knockout in mice is not characteristic for influencing glucose homeostasis (Viollet, 
Andreelli et al. (2003)). In contrast, the α1 knockout mice are anemic, develop 
splenomegaly and a shortened erythrocyte life span (Wang, Dale et al. (2010)).  
In contrast to skeletal and cardiac muscle, the AMP-kinase α1 subunit is described to 
be the predominant subunit in porcine vascular smooth muscle cells and the major 
vasodilative subunit in large conductance vessels like the carotid artery and the aorta 
(Rubin, Magliola et al. (2005); Goirand, Solar et al. (2007)). There is however not yet 
any indication on which subunit regulates the vascular tone of resistance arteries. It is 
also not known which mechanisms are used by the two α subunits to regulate 
vascular tone. 
 Regulation of the AMP-Kinase 
The AMP-kinase is part of a cascade of protein kinases, which means that the AMP-
kinase itself is regulated by upstream kinases (AMPK kinases) and phosphatases. 
The upstream kinases that activate the AMP-kinase via phosphorylation are LKB1, 
CaMKKβ and Tak1, with LKB1 being the most potent of them and the one that is 
influenced by metabolic changes and an increase in the AMP/ATP ratio. AMP-kinase’s 
phosphorylation site is to be found at Thr172 on the α subunit (Hawley, Davison et al. 
(1996)). The AMP-kinase is consequently deactivated by dephosphorylation of Thr172 
via the protein phosphatase 2Cα (PP2Cα). (Suter, Riek et al. (2006); Woods, 
Johnstone et al. (2003); Shaw, Kosmatka et al. (2004); Woods, Dickerson et al. 
(2005); Momcilovic, Hong et al. (2006))  
AMP-kinase is also activated allosterically by AMP, which binds to the γ subunit. AMP 
does not only activate the AMP-kinase allosterically, but also by decreasing the 
dephosphorylation by blocking the phosphatase (Sanders, Grondin et al. (2007); 
Suter, Riek et al. (2006)).  
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While AICAR, a well-known AMP-kinase activator, works by imitating AMP and thus 
activates the AMP-kinase, the regulators used in this thesis, A769662 (A76) and PT1, 
activate the AMP-kinase differently and more effectively.  
Like AMP described above, A76, as first described by Cool, Zinker et al. (2006), is 
said to allosterically activate the AMP-kinase by inhibiting its dephosphorylation. It can 
bind to the β1 subunit inducing an allosteric AMP-kinase activation (Sanders, Ali et al. 
(2007); Scott, van Denderen et al. (2008); Goransson, McBride et al. (2007); 
(Timmermans, Balteau et al. 2014)). Later evidence however indicates that A76 can 
also activate the AMP-kinase independently of the Thr172 phosphorylation (Scott, Ling 
et al. 2014; Huang, Smith et al. 2017).  
The second AMPK activator used in this thesis, PT1, allosterically activates the 
catalytic α subunit directly by inhibiting the autoinhibitory domain that lies on the α 
subunit (Pang, Zhang et al. (2008)). 
 
Figure 4: Regulation of the AMP-kinase (adapted from original of Kreutz (2013)) 
AMP-kinase is activated by phosphorylation via three AMPK upstream kinases, the CaMKKβ, 
the LKB1 and the TAK1, while dephosphorylation via the protein phosphatase 2Cα (PP2Cα) 
inactivates it. It can also be activated allosterically by an increase in AMP or by its specific 
activators A76 and PT1. 
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1.3. Aim of this Study 
While the AMP-kinase has been described as an important enzyme for energy 
homeostasis, there is high interest in how it affects blood flow regulating resistance 
arteries. Our group previously worked on hamster skeletal muscle arteries, but as 
knockout models are mainly available for mice, it was of major importance to: 
• Study whether mouse skeletal muscle arteries present with a significant AMP-
kinase induced regulation of the vascular tone as previously described for 
hamster skeletal muscle arteries 
• Study whether this AMP-kinase induced regulation of the vascular tone can 
also be seen in another kind of vascular bed, e.g. the vascular bed of 
mesenteric arteries 
• Study which α subunits are involved in the regulation of vascular tone and 
whether these subunits have a different effect on calcium-dependent and 
calcium-independent vasodilative mechanisms  
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2. Material  
2.1. Animals  
C57Bl/6 mice were received from Charles River, Sulzfeld, Germany. Global AMPK α1 
and α2 knockout and wild type mice as generated and previously described by Viollet, 
Andreelli et al. (2003); Viollet, Andreelli et al. (2003); Jorgensen, Viollet et al. (2004) 
were derived from Ingrid Fleming, Frankfurt, and further bred in our animal facility. 
Mice were aged 8-44 weeks and age-distribution was comparable in all experimental 
groups. Both male and female mice were used for the experiments with a similar 
gender distribution in treatment and control groups.  
2.2. Experimental Setup and Devices 
Micromanipulator Dual Tool Holder Micromanipulator, 
World Precision Instruments, Berlin, 
Germany 
Microscope for preparing mesenteric 
and skeletal muscle arteries  
Fully automated Leica M205 A, Leica, 
Wetzlar, Germany 
Organ bath  Produced by the workshop of the 
Walter-Brendel-Centre, Munich, 
Germany 
Pipette Puller System  Laser Based Micropipette Puller 
System  
P-2000, Sutter Instruments, 
distribution by Science Products, 
Hofheim, Germany 
Water bath GFL® 1083, GFL, Burgwedel, 
Germany 
 
Workstation 1 for calcium and diameter measurements 
Bryte Box Bryte Box, PTI®, Edison, United 
States of America  
Camera for diameter registration WAT-902B; Watec, Japan  
DeltaScan™ DeltaScan™, PTI®, Edison, United 
States of America 
Inverted microscope Diaphot 300, Nikon, Düsseldorf, 
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Workstation 2 for calcium and diameter measurements  
DeltaRAM V™ DeltaRAM V™, PTI®, Edison, United 
States of America 
Camera for diameter registration CCD-camera: XC-ES50 
Type XC-ES50CE, Sony, Japan  
Inverted microscope Eclipse TS 100, Nikon, Düsseldorf, 
Germany 
Objective: S Fluor, Nikon 
Lamp Power Supply Lamp Power Supply LPS-220B; PTI®, 
Edison, United States of America 
Photomultiplier Photomultiplier Detection System 814, 
PTI®, Edison, United States of 
America 
2.3. Material 
Glass cannulas  Borosilicate glass with filament 
(GB100F-10), Science Products 
GmbH, Hofheim, Germany 
Germany 
Objective: DApo 20UV/340, Olympus 
Lamp Power Supply Lamp Power Supply LPS-220, PTI®, 
Edison, United States of America 
Motor driver  Motor driver MD-5020; PTI®, Edison, 
United States of America 
Optical Chopper  Optical Chopper OC-4000, PTI®, 
Edison, United States of America 
Photomultiplier Photomultiplier Detection System 710, 
PTI®, Edison, United States of 
America 
Power Module  Power Module DeltaRAM, PTI®, 
Edison, United States of America 
Shutter controller  Shutter controller SC-500, PTI®, 
Edison, United States of America 
2 Material 
16 
Filters (0.22 μm pore size)  Filter-System Capacity 1 l, sterile, 
Sigma-Aldrich International GmbH, 
Schnelldorf, Germany 
Perfusor® Line Original-Perfusor® Line, B. Braun, 
Melsungen, Germany  
Silicone tubes  Flexible silicone tubing Tygon®, 
Neolab, Heidelberg, Germany 
Stopcock  Discofix® C, B. Braun, Melsungen, 
Germany 
Surgical scissors and forceps Fine Science Tools, Heidelberg, 
Germany  
Surgical threads Ethilon polyamide monofil 11-0, 
Ethicon, Norderstedt, Germany 
Syringes BD Discardit™ II, Becton Dickinson, 
Fraga, Spain 
Scalpel Carbon Steel Safety Scalpel, Aesculap 
AG/B. Braun, Tuttlingen, Germany 
StepOne™ Real Time PCR System StepOne™ Real Time PCR System, 
Applied Biosystems provided by Fisher 
Scientific GmBh, Schwerte, Germany 
2.4. Software 
BVA 300 (Blood Vessel Analyzer) Blood Vessel Analyzer 300, Hasotec, 
Rostock, Germany 
FeliX32™ FeliX32™, PTI®, Edison, United States 
of America 
2.5. Buffer Solutions and Agents 
 Buffer Solutions 
 MOPS Buffer 
 Concentration  Company 
CaCl2 * 2 H2O 3 mM AppliChem, Darmstadt, Germany 
Distilled water    
EDTA 0.02 mM AppliChem, Darmstadt, Germany 
Glucose 5 mM AppliChem, Darmstadt, Germany 
2 Material 
17 
KCl 4.7 mM AppliChem, Darmstadt, Germany 
MgSO4 * 7 H2O 1.17 mM AppliChem, Darmstadt, Germany 
MOPS 3 mM AppliChem, Darmstadt, Germany 
NaCl 145 mM AppliChem, Darmstadt, Germany 
NaH2PO4 * 1 H2O 1.2 mM AppliChem, Darmstadt, Germany 
Pyruvate 2 mM Sigma-Aldrich, Steinheim, Germany 
To avoid insoluble complexes of CaCl2 with NaH2PO4, CaCl2 was added at the end. 
The pH-value was adjusted by adding NaOH (1 M) until the neutral pH of 7.4 was 
reached. After sterile filtration, the MOPS buffer was stored at 4°C. 
 Incubation Solution (with Fura-2am) 
 Concentration Company 
CaCl2 * 2 H2O 3 mM AppliChem, Darmstadt, Germany 
Distilled water    
EDTA 0.02 mM AppliChem, Darmstadt, Germany 
Fura-2am 2 μM Life Technologies, Darmstadt, 
Germany 
Glucose 5 mM AppliChem, Darmstadt, Germany 
KCl 4.7 mM AppliChem, Darmstadt, Germany 
MgSO4 * 7 H2O 1.17 mM AppliChem, Darmstadt, Germany 
MOPS 3 mM AppliChem, Darmstadt, Germany 
NaCl 145 mM AppliChem, Darmstadt, Germany 
NaH2PO4 * 1 H2O 1.2 mM AppliChem, Darmstadt, Germany 
Pyruvate 2 mM Sigma-Aldrich, Steinheim, Germany 
 Agents 
Agent  Stock solution Company  
A769662 100 mM in DMSO Tocris, distribution by Bio-Techne, 
Wiesbaden-Nordenstadt, Germany 
Acetylcholine 100 mM in distilled 
water 
Sigma-Aldrich, Steinheim, Germany 
Dimethylsulfoxide 
(DMSO) 
(>99.99%) 
 Carl Roth, Karlsruhe, Germany 
Fura-2am 1 mM in DMSO Life Technologies, Darmstadt, 
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Germany 
Iberiotoxin 0.1 mM in distilled 
water 
Tocris, distribution by Bio-Techne, 
Wiesbaden-Nordenstadt, Germany 
Indometacin 100 mM in ethanol Fluka, distribution by Sigma-Aldrich, 
Steinheim, Germany  
Nω-Nitro-L-
Arginine Methyl-
Ester 
10 mM in distilled 
water 
Sigma-Aldrich, Steinheim, Germany 
Manganese 
chloride 
1 M in MOPS Merck, Darmstadt, Germany 
Nifedipine 10 mM in DMSO Sigma-Aldrich, Steinheim, Germany 
Norepinephrine Serial dilution in 
MOPS buffer 
Aventis, Frankfurt am Main, 
Germany 
PT1 100 mM in DMSO Tocris, distribution by Bio-Techne, 
Wiesbaden-Nordenstadt, Germany 
Thapsigargin 10 mM in DMSO Sigma-Aldrich, Steinheim, Germany 
U46619 10 mM in DMSO Tocris, distribution by Bio-Techne, 
Wiesbaden-Nordenstadt, Germany 
Isoflurane  Forene® 100% (V/V), AbbVie 
Deutschland GmbH, Ludwigshafen, 
Germany 
Bacillol  Bacillol 1 l, AF Bode Chemie GmbH, 
Hamburg, Germany 
All agents were stored at the conditions requested by the manufacturer. The agents 
were freshly diluted from aliquots of the stock solutions to the requested concentration 
on the day of the experiments. These dilutions were not kept overnight.  
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 PCR  
Protein/Gene Primer  Sequence 
AMPK-α1/prkaa1 
 
Forward 
Reverse  
CCTTCGGGAAAGTGAAGGT 
GAATCTTCTGCCGGTTGAGT 
AMPK-α2/prkaa2 
 
Forward 
Reverse 
CGACTACATCTGCAAACATGG 
CAGTAATCCACGGCAGACAG 
AMPK-β1/prkab1 
 
Forward 
Reverse 
GGACACGGGCATCTCTTG 
TGCATAGAGGTGGTTCAGCA 
AMPK-β2/prkab2 
 
Forward 
Reverse 
GATCATGGTGGGGAGCAC 
CTGCTGCCAGGGTACAAACT 
AMPK-γ1/prkag1 
 
Forward 
Reverse 
CATCAACATTTTGCACCGATA 
TGCAGGTACACCTCTCTCCA 
AMPK-γ2/prkag2 
 
Forward 
Reverse 
GTGGAGAATTCAGAAAAGCATTC 
GGCCTCTGGAGAAGAGTCCT 
AMPK-γ3/prkag3 
 
Forward 
Reverse 
TCTTTGTGGACCGACGTGT 
AGTAGAGGCCCACGACCTG 
   
HPGRT/hprt1 
 
Forward 
Reverse 
TCCTCCTCAGACCGCTTTT 
CCTGGTTCATCATCGCTAATC 
YWHAZ/ywhaz 
 
Forward 
Reverse 
TAAAAGGTCTAAGGCCGCTTC 
CACCACACGCACGATGAC 
SDHA/sdha 
 
Forward 
Reverse 
CCCTGAGCATTGCAGAATC 
TCTTCTCCAGCATTTGCCTTA 
All primers were obtained from Eurofins MWG Operon, Ebersberg, Germany.  
 
In addition, the following substances were used for the PCR process: 
Substance Company 
REVERTAID reverse transcriptase Fermentas, Sankt Leon-Rot, Germany 
Tri Reagent® Sigma-Aldrich, Steinheim, Germany  
SYBR® Green reagent Power SYBR Green, LifeTechnologies, 
Carlsbad, CA, USA  
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3. Methods 
3.1. Vessel Preparation and Cannulation 
Mice were anesthetized with isoflurane before being killed by cervical dislocation. To 
avoid spreading germs and contamination of the preparation area, the abdomen was 
disinfected with Bacillol before dissection.  
 Preparation of the Mesenteric Arteries 
In order to get to the mesenteric vessels, the abdominal cavity was opened by cutting 
through the abdominal muscles. The mesentery was first separated from the large and 
small intestine starting at the rectum and afterwards from the big vessels (superior 
mesenteric artery and vein). After extracting the mesentery from the mouse, it was 
stored in MOPS buffer at a constant temperature of 4°C. The mesentery was 
subsequently placed into a petri dish also filled with MOPS that was kept on ice. The 
second order mesenteric arteries were then dissected from the surrounding fatty 
tissue and the mesenteric veins using a preparation microscope.  
 
Figure 5: First, second and third generation of mesenteric arteries after preparation 
 Preparation of the Skeletal Muscle Arteries  
In order to dissect the skeletal muscle arteries from the gracilis muscle, the mouse’s 
hind legs were fixed on a board made of styrofoam. After exposing the femoral 
muscles, the thigh was cut off the trunk and the lower leg using a scalpel. The thigh 
was then spread out in a petri dish filled with MOPS buffer. Here, the gracilis artery 
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was prepared after the accompanying vein, the gracilis muscle and the surrounding 
connective tissue had been removed using a preparation microscope. 
These arteries were then stored in an organ bath (also filled with MOPS) at 4°C until 
the set-up was prepared for cannulation.  
Both mesenteric and skeletal muscle arteries were extracted using microsurgical 
instruments. To ensure minimal risk of damaging the arteries, all vessels were 
touched as little as possible. Fatty and connective tissue was removed from the artery 
in the gentlest way as well. 
 Vessel Cannulation 
After preparation, both mesenteric and skeletal muscle arteries were pulled onto the 
pointed ends of glass cannulas that were attached to micromanipulators and filled with 
MOPS. The micromanipulators ensured the precise movements of the cannulated 
vessels segments in the three dimensions of the organ bath that was filled with 
MOPS.  
The glass cannulas were obtained when the middle of a glass micropipette was 
heated by a CO2-Laser (pipette puller). By pulling from both ends the micropipette 
could then be broken in the middle so that two glass cannulas with sharp points and a 
diameter of about 40 µm became available. 
The other blunt end of the glass cannula was connected with a stopcock via a silicone 
tube. The stopcock was linked to a syringe cavity (without plunger) via a Perfusor® 
line. The syringe cavity was filled with 10-15 ml MOPS and could be attached to the 
wall in various heights. This way a hydrostatic pressure of 45 mmHg or 60 mmHg 
could be achieved for the cannulated vessels thus behaving like a pressure 
myograph.  
Now the vessel was pulled onto the first cannula, fixed there with surgical threads and 
perfused at a hydrostatic pressure of 45 mmHg. This way MOPS would flow through 
the vessel and clean it of the remaining blood. Potential holes in the vessel wall (due 
to side branches having been cut off) could be seen when blood leaked from them. 
Afterwards the vessel was pulled onto the second cannula and was likewise fixed 
there with surgical thread. The cannulated vessel was further tested for leaks by 
closing the first stopcock. If a hole was present MOPS would leak through it and the 
hydrostatic pressure would no longer be maintained resulting in the vessel’s shrinking. 
Such a vessel was either discarded or a shorter segment of it was used by pulling the 
vessel further along one of the cannulas. 
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Afterwards the vessel was stretched to its original length by using the 
micromanipulators and was again tested for leakage, as described before. 
 
Figure 6: Set-up for vessel cannulation 
The cannulas are attached to micromanipulators to ensure precise movement of the blood 
vessel in all three dimensions of the organ bath. A transmural pressure of 45/60 mmHg was 
achieved by fixing a syringe cavity filled with MOPS at an appropriate height.  
3.2. Calcium Measurement with Fura-2am 
 Incubation with Fura-2am 
After successfully cannulating the blood vessels, the whole set-up (as described in 
section 3.1.3 Vessel Cannulation) was transported to the calcium workstations. There, 
the MOPS buffer in the organ bath was substituted with 3 ml of the incubation solution 
with the calcium dye Fura-2am (2 μM) (see section 2.5.1.2 Incubation Solution (with 
Fura-2am)). The vessel was incubated for two hours at a physiological temperature of 
37°C and a transmural pressure of 45 mmHg. After one hour of incubation another 
2 ml of the incubation solution was added to the organ bath to compensate for 
evaporation. The COX inhibitor indometacin and the eNOS inhibitor L-NAME were 
added to these 2 ml to block potential endothelium-dependent vasodilation in the 
following experimental protocols (see chapter 3.4.4. Blocking the eNOS and the COX) 
except for the experiments described in section 3.4.5.1 Acetylcholine Dose-Response 
Curve, where the effects of the COX and eNOS were analyzed separately. 
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After two hours of incubation the organ bath solution was exchanged with normal 
MOPS two times before the start of the experiments.  
To avoid bleaching of Fura-2am, both incubation and the following experiments were 
performed in a darkened room. 
 Mode of Action of Fura-2am 
Fura-2am, a fluorescent calcium indicator, was first described by Grynkiewicz, Poenie 
et al. (1985). Since Fura-2 itself is hydrophilic and thus cannot pass the cell 
membranes it was applied as an acetoxymethyl ester. The acetoxymethyl ester Fura-
2am is lipophilic and can thus easily pass the smooth muscle cells’ membranes when 
applied to the organ bath (Roe, Lemasters et al. (1990)). The ester group is then 
removed by the intracellular esterases. As soon as the ester group is removed, Fura-2 
can bind free intracellular calcium ions leading to changes in its fluorescence. 
Adding Fura-2am externally (i.e. to an organ bath) ensures selective loading of 
smooth muscle cells and negligible loading of endothelial cells (Meininger, Zawieja et 
al. (1991)).  
 Measurement of Intracellular Calcium 
As described by Tsien, Rink et al. (1985) the emission spectrum of Fura-2 changes 
when it binds to calcium. Fura-2 (calcium free) has an emission maximum when 
excited at 380 nm, whereas Fura-2 (calcium bound) has this maximum at an excitation 
wavelength of 340 nm.  
Both kinds of Fura-2 (calcium bound and calcium free) emit at the same wavelength of 
510 nm.  
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Figure 7: Excitation and emission spectrum of Fura-2  
The excitation spectrum of Fura-2 depends on the concentration of free versus bound calcium, 
whereas the emission wavelength is not altered by calcium. (Figure created with Fluorescence 
SpectraViewer provided by www.lifetechnologies.com) 
 
Various factors like bleaching or an increase in tissue volume (e.g. in vessel 
constriction) induce changes in the absolute excitation spectrum and the emission 
intensity. These effects can be avoided by using the ratio of the fluorescence 
intensities emitted after excitation at 340 nm and 380 nm (F340, F380), as both of them 
are proportionally affected (Meininger, Zawieja et al. (1991)).  
The absolute values of intracellular calcium can then be calculated by using the ratios 
and the dissociation constant Kd and the following formula of Grynkiewicz, Poenie et 
al. (1985): 
 
[𝐶𝑎2+]𝑖 =  𝐾𝑑 ∗ (
𝑅 − 𝑅𝑚𝑖𝑛
𝑅𝑚𝑎𝑥 − 𝑅
) ∗ (
𝑆𝑓2
𝑆𝑏2
) 
 
[Ca2+]i Intracellular calcium concentration 
Kd Dissociation constant for Fura-2 
R Ratio at any Ca2+ concentration 
Rmin/max Ratios at maximum and minimum Ca2+ saturation 
Sf2 Free dye at λ2 (for Fura-2 λ2=380 nm) 
Sb2 Calcium-bound dye at λ2 (for Fura-2 λ2=380 nm) 
 
The absolute values are thus heavily dependent on Rmin/max, which are further 
dependent on filters and the lamp used. Small changes therefore lead to a large over- 
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or underestimation of the absolute calcium concentration. In addition to this, it is 
difficult to determine the Kd in living cells. Calculating the ratio values (after subtracting 
background fluorescence) instead of absolute values avoided these problems but still 
allowed for changes of intracellular calcium concentrations to be measured reliably 
and reproducibly. (Benham (1989)) 
The ratio values were therefore mainly used throughout this thesis instead of 
calculating the calcium values because the dissociation constant (Kd) for the smooth 
muscle of mouse arteries is not known and depends, amongst others, on local ionic 
strength and pH (Uto (1991)). Ratio values were considered to satisfactorily allow the 
analysis of changes in intracellular calcium levels. 
As each blood vessel has a unique autofluorescence, these autofluorescence values 
needed to be subtracted when calculating the ratio to have vessel-independent 
calcium ratios. Manganese chloride (MnCl2: 8 mM) was used to measure 
autofluorescence as metal ions are described to quench fluorescence dyes as they 
have a much higher affinity to Fura-2 than calcium (Grynkiewicz, Poenie et al. (1985)).  
 
 
 
R: Ratio independent of autofluorescence 
F340/380: Fluorescence intensity at 340 nm or 380 nm 
A340/380: Autofluorescence values at 340 nm or 380 nm after quenching with 
MnCl2 
 
 Structure of the Calcium Workstations 
 Structure of Workstation 1 
The intracellular calcium that was bound to Fura-2 was detected by the DeltaScan™ 
system, which was structured as follows. 
A light beam generated by a xenon lamp (75 W) was diverted to a monochromator for 
either a wavelength of 340 nm or 380 nm by the chopper wheel, which was rotating 
with a frequency of 50 Hz. The monochromatic light beams were then channeled to 
the optical path of an inverted microscope via two different optical fibers. Aperture 
diaphragms were used to eliminate possible artefacts of sutures or tissue residues. 
Fura-2 was alternatingly excited by the two different wavelengths (340 nm or 380 nm). 
R =
(F340 - A340 )
(F380 - A380 )
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As discussed in chapter 3.2.3 Measurement of Intracellular Calcium, both calcium 
bound and calcium free Fura-2 emitted light at the same wavelength (510 nm). Due to 
a band-pass filter, only light of this wavelength was detected by a photomultiplier and 
the resulting signal was sent to the primary data reception unit, the Bryte Box. The 
Bryte Box was connected to a computer, which analyzed the signals with the 
FeliX32™ software. The software related the signal intensities to the exciting 
wavelengths (340 nm and 380 nm) and recorded five values per second. The values 
of autofluorescence had to be subtracted from the fluorescence intensities in an excel 
sheet afterwards. 
A shutter in the light path of the photomultiplier, which was also directly operated by 
the software minimized bleaching of the vessels during experimental breaks.  
 Structure of Workstation 2 
A second system, the DeltaRAM V™, was also used to measure the calcium-
dependent Fura ratio. The structure was similar to that of the DeltaScan™ of 
workstation 1, except that there was only one monochromator, which produced 
alternating light beams of either 340 nm or 380 nm.  
 Measurement of Vessel Diameter 
Both inner and outer vessel diameters were measured using a high-resolution 
camera. A halogen lamp illuminated the vessel. To avoid interference with the calcium 
measurement, a red-light filter was installed to eliminate all wavelengths below 
610 nm.  
Using the blood vessel analyzer software BVA 300, both diameters were recorded 
once per second. As the outer diameter was more precise especially when the vessel 
was highly constricted, it was used throughout this dissertation. The diameter values 
were equally recorded by the Bryte Box and were synchronized with the results from 
the fluorescence intensity measurements. The diameter values were translated to their 
original unit (μm) during analysis following calibration of the system.  
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Figure 8: Structure of workstation 1 (modified original of Kreutz (2013)) 
Producing two monochromatic light beams (at 340 nm and 380 nm), the DeltaScan™ excites 
both calcium-bound Fura-2 with 340 nm and calcium-free Fura-2 with 380 nm. Both kinds of 
Fura-2 emit a wavelength of 510 nm. Due to specific filters, it is ensured that only this 
wavelength is recorded by the photomultiplier and consequently transmitted to the Bryte Box. 
The vessel diameter is registered using a high-resolution camera and using a red-light filter to 
avoid interference with the calcium measurement. The data for the diameter is equally 
transmitted to the Bryte Box, transformed to Volt values and continuously recorded using the 
Felix32™ software. 
3.3. Abbreviations 
Abbreviations for substances  
A76 A769662 
ACh Acetylcholine 
IbTX Iberiotoxin 
MnCl Manganese Chloride  
Nif Nifedipine  
L-NAME Nω-nitro-L-arginine methyl ester 
U46 U46619 
MOPS 3-(N-morpholino)propanesulfonic acid 
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TG Thapsigargin 
 
General Abbreviations  
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
AMPK AMP-kinase 
AMPKK AMPK-kinase 
ATP Adenosine triphosphate 
BkCa-channels Large conductance Ca2+-activated K+ 
channels 
Ca2+ Calcium  
CaM Calmodulin 
CaMKKβ Ca2+/CaM-dependent protein kinase 
kinase β 
cAMP Cyclic AMP 
cGMP Cyclic GMP 
COX Cyclooxygenase 
DAG Diacyl-Glycerol 
eNOS Endothelial nitric oxide synthase 
GMP Guanosine monophosphate 
hprt1/HPRT1 hypoxanthine phosphoribosyltransferase1 
IP3 Inositol trisphosphate 
K+ Potassium  
KATP channel ATP-sensitive potassium channel 
Kd Dissociation constant  
KO Knockout 
LKB1 Liver kinase B1 
MLC Myosin light chain 
MLCK Myosin light chain kinase 
MLCP Myosin light chain phosphatase 
MYPT1 Myosin phosphatase targeting subunit-1 
NO Nitric oxide 
p190-GAP p190-guanosine triphosphatase-activating 
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protein 
PCR Polymerase chain reaction  
PKC Protein kinase C 
PKG Protein kinase G 
PLC Phospholipase Cβ 
PP2Cα Protein phosphatase 2Cα 
RhoA GTPase protein of the Ras homolog gene 
family, member A 
ROCK Rho-associated protein kinase 
sdha/SDHA Succinate dehydrogenase complex, 
subunit A 
SERCA Sarco/endoplasmic reticulum Ca2+-
ATPase 
TAK1 Transforming growth factor β activated 
kinase-1 
WT Wild type 
ywhaz Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
3.4. Protocols 
 PCR 
PCR was performed to analyze the presence and the relative amount of the AMPK 
subunits in mesenteric arteries. The StepOne™ Real Time PCR System and the 
SYBR® Green reagent were used in conjunction with the following primer pairs: 
 
Gene Protein Primer sequence 
prkaa1 AMPK α1 subunit CCTTCGGGAAAGTGAAGGT 
prkaa2 AMPK α2 subunit CGACTACATCTGCAAACATGG 
prkab1 AMPK β1 subunit GGACACGGGCATCTCTTG 
prkab2 AMPK β2 subunit GATCATGGTGGGGAGCAC 
prkag1 AMPK γ1 subunit CATCAACATTTTGCACCGATA 
prkag2 AMPK γ2 subunit GTGGAGAATTCAGAAAAGCATTC 
prkag3 AMPK γ3 subunit TCTTTGTGGACCGACGTGT 
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Three reference primers were also applied: 
 
Gene Protein Primer sequence 
hprt1 HPRT TCCTCCTCAGACCGCTTTT 
ywhaz 14-3-3 protein 
zeta/delta 
TAAAAGGTCTAAGGCCGCTTC 
sdha SDHA CCCTGAGCATTGCAGAATC 
 
As many mesenteric arteries as possible were extracted from one mouse and RNA 
was isolated using the Tri Reagent®. First strand synthesis was then conducted using 
REVERTAID reverse transcriptase together with unspecific primers. (Blodow, 
Schneider et al. (2013)) 
The following protocol was used for first and seconds strand synthesis: 95°C for 10 
minutes (denaturing), which was then followed by 45 cycles of 95°C for 15 seconds 
and 65°C for 60 seconds (annealing and extension). The melting curve was obtained 
from another 15 seconds of 95°C being followed by 60 seconds of 60°C. 
Fluorescence was registered at 95°C.  
 Addition of Agonists 
All agents (NE, U46, ACh, A76, PT1 and the increasing Ca2+-concentrations) were 
kept as standardized stock solutions and freshly diluted in MOPS on the day of the 
experiments. The different substances were then added to the organ bath (filled with 
3 ml of MOPS) using 1000 μl pipettes to obtain the final concentrations.  
The solutions were kept in a water bath before administration to avoid any change in 
the temperature of the organ bath which was set at 37°C. 
An equilibration period of 20 minutes after the end of Fura incubation was kept before 
starting (further) experiments.  
 Vessel-Dependent Disqualifying Factors 
Only the results of vessels that passed a vitality test and constricted by at least 20% of 
the resting outer diameter (on either NE or U46) were included in the final statistical 
evaluation. This constriction was considered as a sign of an intact function of smooth 
muscle cells. Vessels that presented with a Fura-induced fluorescence that did not 
show a relevant decrease between the beginning and ending of the experiments were 
also excluded and not studied further. 
3 Methods 
31 
 Blocking the eNOS and the COX 
To exclude the potential influence of the AMPK on the endothelium-dependent 
vasomotor response, both the endothelial NOS (eNOS) and the production of 
prostacyclin were blocked before the start of the experiments (Horman, Morel et al. 
(2008); Chen, Mitchelhill et al. (1999); Chen, Peng et al. (2009); Chang, Wang et al. 
(2011)). L-NAME (30 μM) was used to block the eNOS and indomethacin (30 μM) was 
used to block the COX and both were added with the second two milliliters of Fura-2 
in the second hour of incubation (see chapter 3.2.1 Incubation with Fura-2am). 
 Dose-Response Curves 
Substances were added in volumes of 1 ml each, while at the same time 1 ml was 
pipetted off the 3 ml (basal) fluid of the organ bath. This method ensured a constant 
fluid level while it also avoided excessive stress on the vessels by exchanging all 3 ml 
of the surrounding fluid in the organ bath. Adding 1 ml and pipetting off another 1 ml 
diluted the added 1 ml of fluid by one third. To compensate for this dilution, the 
concentration of the added substances had to be three times as high as the desired 
concentration in the organ bath. All concentrations mentioned in this thesis were the 
concentrations present in the organ bath. 
After the vasoconstrictors, norepinephrine (NE) or U46, were administered, we waited 
either five minutes in the case of U46 or ten minutes in the case of norepinephrine for 
the vasoconstriction to reach a steady state before starting the dose-response 
experiments. In order to not dilute the constrictors during the dose-response curves, 
they were added simultaneously to the vasodilators in one third of the concentration 
that they were originally pipetted into the organ bath. 
Please note that in all dose-response and calcium desensitization figures that follow 
the darker colors represent higher concentrations and the lighter colors lower 
concentrations. 
 Acetylcholine Dose-Response Curve 
To test the effect of the endothelial stimulus acetylcholine in skeletal muscle and 
mesenteric arteries, cumulative dose-response curves were obtained in the absence 
of L-NAME and indometacin. For these curves the vessels were pre-constricted with 
the thromboxane analogue U46 (1 μM) and afterwards the concentration of 
acetylcholine was increased every 3 minutes (0.01 μM – 30 μM). Maximal dilation was 
achieved by adding nifedipine (5 μM) at the end of the experiments.  
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 A76/PT1 Dose-Response Curve 
To analyze the vasomotor effects of AMP-kinase stimulation, dose-response curves 
were performed on vessels pre-treated with L-NAME and indometacin (see chapter 
3.4.4 Blocking the eNOS and the COX). The vessels were pre-constricted with 
norepinephrine (1 μM). The concentration of the substance that was tested (A76: 1 μM 
– 100 μM; PT1: 0.3 μM – 30 μM) was increased every 5 minutes. In order to relate 
these results to maximal dilation, nifedipine (5 μM) was added at the end of the 
experiments. 
 
       Nif 5 μM 
  A76 
 1 μM 
A76  
3 μM 
A76  
10 μM 
A76  
30 μM 
A76 
100 μM 
 
NE 1 μM        
0 min  10 min 15 min 20 min 25 min 30 min 35 min 
 
       Nif 5 μM 
  PT1  
0.3 μM 
PT1  
1 μM 
PT1  
3 μM 
PT1  
10 μM 
PT1  
30 μM 
 
NE 1 μM        
0 min  10 min 15 min 20 min 25 min 30 min 35 min 
 
When testing the effect of SERCA inhibitor TG and BkCa-channel blocker IbTx on the 
dilation mediated by either of the two AMPK α subunits, these substances were added 
5 minutes after the addition of the vasoconstrictor NE (1 μM). They were added to the 
organ bath together with one third of the NE concentration to ensure a continuous 
level of NE. In the case of IbTx (100 nm) the A76 dose-response was done as 
described before, but with an added level of one third (30 nm) of IbTx at every step of 
A76.  
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TG (1 μM), however, induced a substantial dilation of around 90% 8 to 10 minutes 
after administration, starting at around 3-4 minutes after application and due to the 
fact that A76 took 3 to 5 minutes to reach a dilatory steady state, only a single 
concentration of A76 of 100 μM was used to analyze the effect of SERCA on the 
respective subunits. A third of the aforementioned TG (1 μM) was added to the 
100 μM A76 dosage to ensure a continuous level of TG.  
Just as described before nifedipine (5 μM) was added at the end of the experiments in 
order to relate the results to maximal dilation. 
       Nif 5μM 
  A76 1μM A76 3μM A76 10μM A76 30μM A76 
100μM 
 
 IbTx 
(100nM) 
      
NE 1μM  
0 min 5 min 10 min 15 min 20 min 25 min 30 min 35 min 
 
 
 Calcium-Desensitization Curves 
To test the effect of the AMPK on calcium desensitization, the vessels’ calcium stores 
were initially depleted by keeping the vessels in calcium-free MOPS for 3 minutes. 
The vessel was then depolarized for another 3 minutes using a potassium-rich 
(125 mM) MOPS (0 mM Ca2+) to open voltage-dependent calcium channels. By 
increasing the extracellular calcium concentration step by step, a corresponding 
increase of the intracellular concentration was achieved (Bolz, Galle et al. (2000)). 
MOPS with increasing calcium concentrations (0.5 mM, 1 mM, 2 mM, 3 mM) was 
added every 3 minutes. In contrast to the dose-response curves all 3 ml of the 
respective MOPS had to be exchanged. 
After administrating the MOPS with the highest calcium concentration (3 mM), the 
organ bath was washed with normal MOPS buffer and the vessel was equilibrated for 
   Nif 5μM 
  A76 100μM  
 TG 1μM   
NE 1μM    
0 min 5 min 10 min 15 min 
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20 minutes before the start of the second part of the experiment testing the effect of 
AMPK stimulation by A76. A76 was added to the organ bath during the equilibration 
period and to all the substances used in the experiment.  
  Ca2+ 0.5mM Ca2+ 1mM Ca2+ 2mM Ca2+ 3mM 
Ca2 0mM K+ 125mM, 
Ca2+ 0mM 
    
0 min 3 min 6 min 9 min 12 min 15 min 
 
 Analysis 
The quantitative analysis was performed with Microsoft Office Excel 97-2004 and 
SigmaPlot 12.0 (Systat Software Inc). 
SigmaPlot was also used to generate the graphs presented in this thesis. All results 
are presented as mean values ± SEM. For all analyses, steady state values were 
used. 
 Analysis of PCR 
The relative amount of the AMP-kinase’s subunits as obtained by PCR was 
normalized to the mean of the three reference primers (Blodow, Schneider et al. 
(2013). 
 Analysis of Dose-Response Curves 
The constriction induced by NE or U46 was normalized to the maximal diameter 
obtained at a steady state at the end of the experiment after administration of 
nifedipine (in mesenteric arteries) or the highest concentration of ACh (in skeletal 
muscle arteries, since in these arteries the highest concentration of Ach already 
induced maximal dilatation). 
 
𝑐𝑜𝑛𝑠𝑡𝑟𝑖𝑐𝑡𝑖𝑜𝑛(%) =  
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑁𝐸 𝑜𝑟 𝑈46(𝜇𝑚) −  𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑚𝑎𝑥(𝜇𝑚)
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑚𝑎𝑥(𝜇𝑚)
 
 
diameterNE or U46 Diameter (μm) after administration of vasoconstrictor (NE 
or U46) 
diametermax Diameter (μm) after administration of nifedipine or highest 
concentration of ACh in skeletal muscle arteries 
 
The accompanying increase of the Fura ratio was also normalized to the minimal ratio. 
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𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜(%) =  
𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑁𝐸 𝑜𝑟 𝑈46 −  𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑚𝑖𝑛
𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑚𝑖𝑛
 
 
Fura ratioNE or U46 Fura ratio after administration of vasoconstrictor (NE or 
U46) 
Fura ratiomin Fura ratio after administration of nifedipine or highest 
concentration of ACh in skeletal muscle arteries 
 
For the analysis of the dose-response curves, the relative dilation initiated by a 
particular agonist’s concentration was calculated by normalizing absolute dilation to 
the maximal possible dilation (as obtained after administration of nifedipine/ACh (in 
skeletal muscle arteries)). In the case of skeletal muscle arteries, maximal dilation and 
maximal decrease of calcium was usually already obtained at the highest 
concentration of ACh (1 μM). Here, nifedipine did not increase the diameter further.  
 
𝑑𝑖𝑙𝑎𝑡𝑖𝑜𝑛(%) =
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑎𝑔𝑜𝑛𝑖𝑠𝑡(𝜇𝑚) − 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑁𝐸/𝑈46(𝜇𝑚) 
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑚𝑎𝑥(𝜇𝑚) − 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝑁𝐸/𝑈46(𝜇𝑚)
   
 
diameteragonist Diameter (μm) after administration of agonists (ACh, 
A76 or PT1) 
diameterNE/U46 Diameter (μm) after administration of vasoconstrictor 
(NE or U46) 
diametermax  Diameter (μm) after administration of nifedipine 
(Exception: diameter (μm) after administration of the 
highest concentration of ACh in ACh dose-response 
curves of skeletal muscle arteries) 
 
The relative decrease of the Fura ratio initiated by a particular agonist’s concentration 
was equally normalized to the minimal values obtained after application of nifedipine. 
As mentioned before, the only exceptions to this rule were the acetylcholine dose-
response curves of the skeletal muscle arteries, which were compared to the maximal 
decrease on addition to the highest concentration of ACh (1 μM). 
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𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜(%) = −
𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑎𝑔𝑜𝑛𝑖𝑠𝑡  − 𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑁𝐸/𝑈46
𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑚𝑖𝑛 − 𝐹𝑢𝑟𝑎 𝑟𝑎𝑡𝑖𝑜𝑁𝐸/𝑈46 
   
 
Fura ratioagonist Ratio after administration of agents (ACh, A76 or PT1) 
Fura ratioNE/U46 Ratio after administration of vasoconstrictor (NE or 
U46) 
Fura ratiomin  Ratio after administration of nifedipine  
(Exception: ratio after administration of the highest 
concentration of ACh in ACh dose-response curves of 
skeletal muscle arteries) 
 
Autofluorescence values were subtracted from the original fluorescence intensities 
beforehand.  
 
Statistical analysis was performed using SigmaPlot 12.0. Differences between the 
tested groups were assumed to be relevant at a significance level of 5% (p<0.05).  
Possible differences of constriction or dilation between two independent groups were 
examined using a two-tailed t-test for unpaired data. A Shapiro-Wilk test was 
performed beforehand to check for normal distribution and a Brown-Forsythe test to 
check for equal variance. If either of these two tests failed, a Mann-Whitney rank sum 
test was performed.  
A two-way Anova (Holm-Sidak test) was performed to find significant differences in 
dose-response curves. The two-way Anova tested normally distributed data with a 
Holm-Sidak test and in case the data was not normally distributed, a Kruskal Wallis 
test was applied. Both of these tests compare two independent variables 
(concentration of the stimulator and the kind of vessel/genotype) with a dependent 
variable (diameter/ratio).  
 Analysis of Calcium Desensitization Curves 
The effect of A76 on AMPK-induced calcium desensitization was analyzed by plotting 
the absolute instead of relative data of the blood vessel diameter and its Fura ratio. 
The need for absolute data resulted from bleaching artefacts that tainted the relative 
data sets. 
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A non-linear regression analysis was used to compare the changes in both diameter 
and Fura ratio. For a non-linear regression analysis, two individual exponential curves 
had to be obtained from the two original data sets (before and after adding A76) and 
then be compared to a combined curve resulting in a pooled data set. If the separate 
curves were a significantly better fit than the combined curve, this equaled a 
significant difference between the data sets. Via regression analysis, sum of square 
data (SS) and degrees of freedom (df) were acquired. Using the following formulas, F 
values were calculated, which were then transformed to p values using the Graphpad 
software2, whereby p values smaller than 0.05 represented a significant difference 
between two groups. (Bolz, de Wit et al. (1999); Motulsky and Ransnas (1987)) 
 
𝐹 =  
(𝑆𝑆𝑝𝑜𝑜𝑙 −  𝑆𝑆𝑠𝑒𝑝)
(𝑑𝑓𝑝𝑜𝑜𝑙 − 𝑑𝑓𝑠𝑒𝑝)
⁄
𝑆𝑆𝑠𝑒𝑝
𝑑𝑓𝑠𝑒𝑝
⁄  
 
 
𝑆𝑆𝑠𝑒𝑝 =  𝑆𝑆1 − 𝑆𝑆2 
 
𝑑𝑓𝑠𝑒𝑝 =  𝑑𝑓1 − 𝑑𝑓2 
 
𝐹 F value 
𝑆𝑆𝑝𝑜𝑜𝑙 Sum of squares for pooled data 
𝑆𝑆𝑠𝑒𝑝 Added sum of squares for individual data 
𝑆𝑆1/2 Individual sum of squares before (1) and after (2) A76 
𝑑𝑓𝑝𝑜𝑜𝑙 Degrees of freedom for pooled data 
𝑑𝑓𝑠𝑒𝑝 Added degrees of freedom for individual data 
𝑑𝑓1/2 Individual degrees of freedom before (1) and after (2) 
A76 
 
  
                                            
2 Graphpad software: www.graphpad.com  
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4. Results 
4.1. Comparison of Skeletal Muscle Arteries and Mesenteric 
Arteries 
 General Vessel Characteristics 
The experiments for this doctoral thesis were performed from February 2011 until 
September 2015 with the first 6 months being used to learn the preparation technique.  
In the following months 166 vessels were prepared for the experiments. 127 
mesenteric and skeletal muscle arteries could finally be analyzed using the criteria 
described before (see chapter 3.4.3 Vessel-Dependent Disqualifying Factors). From 
the 39 vessels that could not be used, 18 constricted less than 20% of the original 
diameter on addition of norepinephrine or U46, while the rest had to be discarded due 
to technical or vessel related problems (e.g. broken organ baths, no decrease of the 
Fura ratio on addition of nifedipine or ongoing vasomotion). 
The average maximal diameter for all mesenteric arteries studied in this thesis was 
224.4 ± 4.3μm while skeletal muscle arteries had an average maximal diameter of 
183.0 ± 8.3μm. In order to analyze potential differences between the smaller skeletal 
muscle arteries and mesenteric arteries, a subgroup of smaller mesenteric arteries 
was chosen to insure comparability (diameter of skeletal muscle arteries (n=4): 
183.0 ± 8.3 μm; diameter of comparable mesenteric arteries (n=7): 186.4 ± 11.6 μm). 
 Constriction 
In both mesenteric and skeletal muscle arteries, the thromboxane analogue U46 
(1 μM) induced virtually the same relative vasoconstriction in relation to maximal 
diameter (skeletal muscle arteries: -29.4 ± 3.0%; mesenteric arteries: -30.9 ± 2.1%). 
The Fura ratio was, however, significantly increased in the skeletal muscle arteries 
despite comparable starting levels (skeletal muscle arteries: +62.1 ± 10.0%; 
mesenteric arteries: +33.7 ± 7.1%). 
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Figure 9: Effect of U46 on skeletal muscle arteries and mesenteric arteries  
U46 (1 μM) induced comparable constriction in both skeletal muscle (n=4) and mesenteric arteries 
(n=7), but a significantly higher Fura ratio in skeletal muscle arteries than in mesenteric arteries.  
(* < 0.05) t-test  
 Relaxation 
A single dose of acetylcholine (10 μM), administered as part of a pre-test before the 
Fura-2 incubation, elicited an almost complete (95.4 ± 0.8%) dilation of the mesenteric 
arteries. As the test was done before the Fura-2 incubation, the Fura ratio could not 
be determined at this stage. The test was, however, not done in vessels that 
underwent further endothelial testing like the skeletal muscle arteries. As for the other 
experiments further analyzing the effects of the AMP-kinase on smooth muscle cells, it 
was also not performed on a continuous basis as an endothelial-independent effect 
was studied.  
To test and compare the endothelial function of these different types of vessels 
however, the acetylcholine-induced dilation was studied in more detail by obtaining a 
dose-response curve (0.01 μM – 1 μM) after incubation with Fura-2.  
In skeletal muscle arteries, increasing doses of acetylcholine induced dilations in a 
dose-dependent manner. These dilations were accompanied by respective decreases 
of the Fura ratio. In contrast, the mesenteric arteries, despite having responded well to 
the initial dose of acetylcholine subsequently only showed a small response to 
acetylcholine which was virtually independent of the applied dose (see Figure 10). 
While the skeletal muscle arteries dilated almost completely to an acetylcholine 
concentration of 0.3 μM (+97.5 ± 1.1%), the mesenteric arteries reacted much less 
4 Results 
40 
and only presented with a small dilation even to the highest acetylcholine 
concentration of 30 μM (+16.8 ± 11.9%). 
The Fura ratio of the mesenteric arteries also did not change significantly even at 
30 μM acetylcholine (-36.7 ± 10.5%) while the ratio of the skeletal muscle arteries 
almost declined to the reference value that is obtained after adding acetylcholine 1 μM 
(see chapter 3.4.7.2 Analysis of Dose-Response Curves) at 0.3 μM acetylcholine  
(-93.3 ± 2.0%).  
 
 
Figure 10: Dose-dependent effects of acetylcholine (ACh) in skeletal muscle arteries and 
mesenteric arteries 
ACh induced a significant dilation and a decrease of the Fura ratio in skeletal muscle arteries 
(n=4), but hardly any dilation or decrease of the Fura ratio in mesenteric arteries (n=7).  
(** < 0.01; *** < 0.001) Two-Way Anova 
To further clarify the relative contribution of the endothelial component NO in the 
dilation of the skeletal muscle arteries, the eNOS was blocked by L-NAME (30μM). 
The skeletal muscle arteries still dilated to comparable values (with L-NAMEACh 1 μM: 
+96.3 ± 3.5%; without L-NAMEACh 1μM: 107.2± 7.5), but there was a significant decline 
of the drop in Fura ratio compared to vessels not treated with L-NAME (with L-
NAMEACh 0.3 μM: -70.9 ± 4.2%; without L-NAMEACh 1μM: -118.6 ± 22.7%).  
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Figure 11: Influence of L-NAME on ACh-induced dilation in skeletal muscle arteries 
The addition of L-NAME (30 μM) did not significantly influence the dilation to increasing doses 
of A76 (n=4 for both groups), but did significantly reduce the decline of the Fura ratio. (* < 0,05) 
Two-Way Anova 
The endothelium-independent vasodilator nifedipine (5 μM), which was applied 
towards the end of the experiments, induced an almost maximal dilation in both, 
skeletal muscle and mesenteric arteries (skeletal muscle arteries: +84.7 ± 9.1%; 
mesenteric arteries: +86.8 ± 5.0%). The Fura ratio decreased similarly in both cases 
to or even below the basal values measured before the application of the 
vasoconstrictor (skeletal muscle arteries: -140.5 ± 52.6%; mesenteric arteries  
-102.1 ± 14.0%). Thus, there was no difference in the endothelium-independent 
vasodilation of skeletal muscle and mesenteric arteries.  
The reasons for the differences between muscle and mesenteric arteries with regard 
to their response to acetylcholine were not studied further. The endothelium-
independent smooth muscle cell responses were regarded as more important than the 
endothelium-dependent responses since, as shown before in hamster vessels, the 
AMP-kinase induces vasodilation in an endothelium-independent manner (Schneider, 
Schubert et al. (2015)). 
All further experiments were performed in mesenteric arteries. Due to their multitude, 
these arteries were considered to allow simultaneous measurements of vascular 
reactions and harvesting for protein determination from the same animal.  
4 Results 
42 
 
Figure 12: Effects of nifedipine on skeletal muscle arteries and mesenteric arteries  
Nifedipine (5 μM) induced dilation and a decrease of the Fura ratio to basal levels in both 
skeletal muscle arteries (n=4) and mesenteric arteries (n=7). t-test 
4.2. AMP-Kinase in Mesenteric Arteries 
 Expression of AMP-Kinase’s Subunits in Mesenteric Arteries 
In order to confirm the expression of the AMP-kinase in small mesenteric arteries and 
to analyze which of its subunits were present, PCR was performed in vessels of 
C57Bl/6 mice. 
Figure 13 shows that the Prkag2 gene encoding the regulatory γ2 subunit was most 
expressed, followed by both the Prkaa1 and Prkaa2 genes, coding for the catalytic α1 
and α2 subunits (γ2: 2.2 ± 0.8; α1: 1.6 ± 0.3 α2: 1.1 ± 0.2). All subunits were expressed 
in mesenteric arteries of C57Bl/6 mice except the γ3 subunit, which was not found in 
these vessels. 
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Figure 13: Relative expression levels of AMPK subunits in mesenteric arteries 
All AMPK subunits were expressed in mesenteric arteries except the regulatory γ3 subunit, with 
the regulatory γ2 subunit most expressed, followed by the catalytic α1 and α2 subunits (n=3).  
 Influence of A76/PT1 on Mesenteric Arteries 
Two different stimulators of the AMP-kinase, A76 and PT1, were used to analyze the 
effect of AMP-kinase activation concerning the vascular tone of mesenteric arteries. 
These two compounds are chemically not related and activate the AMP-kinase 
through different target mechanisms (see section 1.2.3 Regulation of the AMP-
Kinase). 
Both A76 and PT1 led to a dose-dependent dilation and in the case of A76 we also 
observed a concomitant dose-dependent decrease of the Fura ratio (as PT1 
interacted with the Fura-2am signal the calcium values were not measured when PT1 
was applied, as they were not representative). Typical original recordings are shown 
in Figure 14. 
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Figure 14: Dose-dependent dilation and Fura decrease on addition of A76  
(red arrows) or PT1 (red arrows) in a mesenteric artery preconstricted with 
norepinephrine (1 μM) (blue arrows) (green arrows symbolize addition of 5 μM nifedipine)  
Vessels treated with either of the two presented with a dose dependent dilation  
(A76: 30 – 100 μM; PT1: 10 – 30 μM). Maximal dilation and maximal decrease of the 
ratio was obtained at A760.1%DMSO 100 μM (dilation: +93.4 ± 3.2%; Fura ratio:  
-79.9 ± 6.7%) and PT10.03%DMSO 30 μM (dilation: +72.1 ± 12.1%). Concentrations of 
A76 above 10 µM or PT1 above 3 µM led to a significant dilation and a significant 
decrease of the Fura ratio when applying A76. As seen in Figure 15 and Figure 16 the 
control vessels treated with increasing doses of DMSO (0.001% – 0.1%), the solvent 
of A76 and PT1 did not dilate significantly. The observed decrease of the Fura ratio 
was due to time-dependent bleaching of Fura-2. The bleaching reduced the 
fluorescence signal obtained at 340 nm more than the signal obtained at 380 nm and 
did thus not represent a true Ca2+ decrease.  
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Figure 15: A76-induced dose-dependent dilation and decrease of the Fura ratio 
A76 induced a significant dilation and a decrease of the Fura ratio in mesenteric arteries (n=4). 
In contrast to this, the sole use of the solvent (DMSO) did not elicit any significant dilation (n=4). 
(**<0.01; ***<0.001) Two-Way Anova 
 
 
Figure 16: PT1-induced dose-dependent dilation 
PT1 induced a significant dilation in mesenteric arteries (n=4) compared to DMSO-treated 
control vessels (n=4). (***<0.001) Two-Way Anova 
 Calcium Sensitivity 
Our group’s previous experiments in hamster vessels have already shown that the 
AMP-kinase does not only dilate blood vessels by reducing the concentration of 
intracellular Ca2+ in smooth cells but also by reducing the smooth muscle cells’ Ca2+ 
sensitivity. Here, we studied whether this was also the case in mouse vessels.  
4 Results 
46 
Due to the previously described interaction of PT1 and Fura-2am, experiments to test 
the effect of the AMP-kinase on Ca2+ sensitivity were only done with A76. Typical 
original recordings are shown in the following figure (see Figure 17). 
 
Figure 17: Dose-dependent constriction and Fura increase on addition of increasing doses of extracellular 
Ca2+ in a mesenteric artery with and without additional A76  
A stepwise increase of extracellular Ca2+ (0.5 mM, 1 mM, 2 mM, 3 mM) led to an 
increase of the Fura ratio in a depolarized and Ca2+-depleted vessel (MOPS used: 
Ca2+ free, 125 mM K+) thus indicating a simultaneous increase in intracellular free 
Ca2+ (Fura ratio at Ca2+ 0 mM: 0.58 ± 0.03, Fura ratio at Ca2+ 3 mM: 0.84 ± 0.07). This 
increase in intracellular free Ca2+ led to an increasing vasoconstriction (diameter at 
Ca2+ 0 mM: 150.8 ± 10.6 μm, diameter at Ca2+ 3 mM: 87.3 ± 10.5 μm). If the vessels 
were pretreated with A76 this constriction was significantly reduced (p=0.04) (diameter 
at Ca2+ 0 mM: 153.0 ± 11.9 μm, diameter at Ca2+ 3 mM: 111.8 ± 11.4 μm), though the 
increases of the Fura ratio were not altered (Fura ratio at Ca2+ 0 mM: 0.60 ± 0.03, 
Fura ratio at Ca2+ 3 mM: 0.87 ± 0.08), indicating calcium desensitization of the 
contractile apparatus.  
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Figure 18: Effect of A76 on Ca2+ sensitivity  
Vessels pre-treated with Ca2+-free MOPS (K+ 125 mM) were treated with increasing doses of 
extracellular Ca2+ (0.5 mM, 1 mM, 2 mM, 3 mM) with and without A76 (100 μM). There was a 
significantly reduced constrictor response when A76 was added. (***<0.001) Non-linear 
regression analysis  
 The Relative Role of the Different AMP-Kinase’s α Subunits as Studied 
in Knockout Mice 
 Basal Vascular Tone 
At first, we studied whether the unstimulated vessels exhibited a basal tone i.e. 
without adding a vasoconstrictor. Under these conditions, it was expected that 
nifedipine would induce a vasodilation. In α1 and the α2 knockout vessels and vessels 
of the corresponding wild type animals no significant vasodilation on addition of 
nifedipine could be observed (data not shown), thus indicating the absence of a basal 
tone. 
 Reaction to Vasoconstrictors 
In a further step, we studied whether knocking out one of the AMP-kinase’s α subunits 
affected the vessels’ response to the vasoconstrictor norepinephrine (1 μM).  
There was no difference between the α1 knockouts and their wild type controls for 
both constriction (KO: −39.0 ± 4.5%; WT: −41.4 ± 5.4%) and the accompanying 
increase of the Fura ratio (KO: +25.9 ± 3.7%; WT: +47.8 ± 11.6%). 
In α2 knockout vessels, however, constriction to norepinephrine was significantly 
stronger than in the corresponding wild type controls (KO: −41.5 ± 3.1%;  
WT: -29.1 ± 3.6%), while there was no difference regarding the change of the Fura 
ratio (KO: +45.1 ± 13; WT: +43.3 ± 7.8). 
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Figure 19: Effect of norepinephrine on α1 and α2 wild type and knockout vessels  
Norepinephrine (1 μM) led to a comparable constriction and increase of the Fura ratio in α1 
knockout (n=4) and wild type vessels (n=5). In α2 knockout vessels (n=4) constriction to 
norepinephrine (1 μM) was significantly higher than in the corresponding wild type vessels. 
(n=4), while there was no difference in the Fura ratio. (*<0.05) t-test  
Receptor-independent vasoconstriction for knockout and wild type vessels was then 
analyzed by comparing constriction to depolarization by K+ (125 mM). Unlike 
norepinephrine-induced constriction, there was no difference between both knockouts 
and their respective wild type counterparts concerning both constriction and the Fura 
ratio on addition of K+ (125 mM).  
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Figure 20: Effect of depolarization on α1 and α2 wild type and knockout vessels 
Depolarization by K+ (125 mM) induced equivalent constriction and a comparable increase of 
the Fura ratio in α1 and α2 wild type (nα1=6; nα2=4) and knockout (nα1=4; nα2=4) vessels. t-test 
 Response to Specific AMP-Kinase Activators 
4.2.4.3.1. Response to PT1 
The AMPK activator PT1 led to dose-dependent dilation in α2 knockout vessels, which 
did not differ from the response of the respective wild type controls. Virtually identical 
maximal vasodilation was achieved by the highest concentration of PT1 (30 μM) in 
both wild type (+72.1 ± 12.1%) and knockout (+67.2 ± 10.9%) vessels with their EC50 
values not being significantly different either (WT: 5.7 ± 1.1 μM; KO: 9.1 ± 1.3 μM).  
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Figure 21: Effect of PT1 on α2 wild type and knockout vessels 
PT1 induced dose-dependent and almost maximal dilation in α2 knockout vessels (n=6) that 
was comparable to wild type vessels (n=4). Two-Way Anova 
In α1 knockout vessels PT1 led to an increased maximal dilation compared to wild 
type vessels. There was already a tendency for stronger dilation in the knockout for 
lower PT1 concentrations (1–3 μM), but this was not significant (p1 μM=0.203; 
p3 μM=0.131). Dilation to higher concentrations of PT1 (10–30 μM) was, however, 
significantly enhanced compared to the wild type (KO30 μM: +92.2 ± 3.2%; WT30 μM: 
+63.4 ± 7.3). EC50 values were, however, not changed, while the aforementioned 
maximum response was increased (KO: 5.3 ± 0.004 μM; WT: 7.4 ± 1.5 μM).  
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Figure 22: Effect of PT1 on α1 wild type and knockout vessels 
PT1-induced dilation was equally dose-dependent, but significantly enhanced in α1 knockout 
vessels (n=5) compared to the wild type (n=5). (***<0.001) Two-Way Anova 
4.2.4.3.2. Response to A76  
A76, the other AMPK-activator that was tested also led to a concentration-dependent 
dilation and decrease of the Fura ratio in α2 knockouts. As with PT1, there was no 
difference between the two groups concerning both dilation (KOA76 100 μM: 
+88.0 ± 3.3%; WTA76 100 μM: +93.4 ± 3.2%) and Fura ratio (KOA76 100 μM: -72.6 ± 9.2%; 
WTA76 100 μM: -79.9 ± 6.7%). EC50 values also did not differ significantly  
(KO: 34.5 ± 6.7 μM; WT: 29.3 ± 5.5 μM). 
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Figure 23: Effect of A76 on α2 wild type and knockout vessels 
A76-induced dilation and the decrease of the Fura ratio in α2 knockout vessels (n=4) were not 
different from wild type vessels (n=4). Two-Way Anova 
In α1 knockout vessels, however, there was once again a tendency towards a stronger 
dilation than in the wild type vessels though the maximal response was not altered. 
Consequently, the EC50 values in α1 knockout vessels were significantly lower than 
those in wild type vessels (KO: 23.3 ± 1.6 μM; WT: 39.8 ± 4.9 μM). Even if the 
vasodilation was enhanced in the α1 knockout, there was no difference in the dose-
dependent decrease of the Fura ratio at any point.  
 
Figure 24: Effect of A76 on α1 wild type and knockout vessels 
A76 induced increased dilation, but no difference in the Fura ratio in α1 knockout vessels (n=4) 
compared to wild type (n=5). (*<0.05; ***<0.001) Two-Way Anova 
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 Differences in the Mechanisms of Calcium Decrease 
4.2.4.4.1. Influence on BkCa-Channel-dependent Calcium Control 
As other experiments in our lab indirectly suggested, the AMP-kinase’s α1 subunit 
might decrease intracellular Ca2+ in vascular smooth muscle cells by activating the 
BkCa-channel, while the α2 subunit might do so by activating SERCA. The influence of 
A76 on these two calcium-decreasing mechanisms was consequently tested with the 
SERCA blocker thapsigargin (TG) and the BkCa-channel inhibitor iberiotoxin (IbTx) 
and compared in both types of AMP-kinase knockouts.  
In α2 knockout vessels pre-treated with IbTX (100 nM) there was less dilation 
specifically on higher concentrations of A76 (30 μM and 100 μM) than in equally 
treated wild type vessels (KOA76 100 μM: +70.1 ± 4.0%, WTA76 100 μM: +91.4 ± 2.5%). 
Surprisingly, despite there still being a substantial vasodilation there was an increase 
of the Fura ratio at 30 μM and 100 μM of A76 in α2 knockout compared to wild type 
vessels (KOA76 100 μM: +105.3 ± 22.9%, WTA76 100 μM: -55.3 ± 19.6%). This increase 
could be blocked by adding the ORAI blocker YM 58483 (1 μM) (seen in pilot 
experiments).  
EC50 values were, however, not significantly different between the two groups  
(KO: 37.6 ± 1.9 μM; WT: 33.8 ± 5.6 μM). 
Further investigations revealed that the calcium signal producing this increase in the 
Fura ratio may have mainly originated from the outermost vessel layers, so that this 
calcium signal was considered to originate partly from adventitial non-muscle cells or, 
alternatively, to be due to an unspecific side effect of the treatment with iberiotoxin in 
α2 knockout mice (as it was not seen in BkCa knockout mice). It is also conceivable 
that an increase of calcium occurred in a cellular compartment which did not lead to 
vasoconstriction. However, this was not further analyzed in the context of the present 
study.  
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Figure 25: Effect of iberiotoxin (IbTX) on A76-related dilation and decrease of the Fura 
ratio in α2 wild type and knockout vessels 
In α2 knockout vessels (n=10) pre-treated with IbTx (100 nM) A76 induced less dilation and 
even an increase of the Fura ratio compared to α2 wild type vessels (n=6). The increase of the 
Fura ratio on 100 μM A76 could be blocked by the ORAI blocker YM 58483 (1 μM) (seen in pilot 
experiments). (**<0.01; ***<0.001) Two-Way Anova 
When pre-treating α1 wild type and knockout vessels with IbTx (100 nm) there was no 
essential difference between the two dose-response curves. The subanalysis showed 
that there was only a significantly increased dilation in the α1 knockout vessels at 
30 nm of A76 (WT30 μM: +21.3 ± 5.5%, KO30 μM: +38.5 ± 6.6%), while there was no 
difference at 100 nm of A76. There was, however, no change in the Fura ratio, where 
a comparable steady state could be seen until 30 nm of A76 followed by a similar drop 
to the highest concentration of A76. EC50 values were similar between the two groups 
(KO: 32.8 ± 4.2 μM; WT: 43.4 ± 3.1 μM). 
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Figure 26: Effect of iberiotoxin (IbTX) on A76-related dilation and decrease of the Fura 
ratio in α1 wild type and knockout vessels 
In IbTx-pretreated vessels there was no essential difference in both vasodilation (with only a 
singular concentration of A76 leading to a significantly increased vasodilation) and change of 
the Fura ratio in α1 knockout vessels (n=4) compared to wild type vessels (n=4), while there was 
no difference in the change of the Fura ratio. (*<0.05) Two-Way Anova 
To assess for potential side effects of the pharmacological inhibition of BkCa-channels 
by IbTX, A76 induced dilations were studied in BkCa knockout mice in an additional 
series of experiments. As shown in Figure 27 and comparable to the α1 knockouts, 
there was a tendency for stronger dilation at lower concentrations of A76 (1–10 μM), 
but it was only significantly increased at a concentration of A76 30 μM in BkCa 
knockouts (BkCa KO: +68.1 ± 6.1%; BkCa WT: +45.6 ± 3.7%). There was, however, 
no difference in the change of Fura ratio between the knockout and the wild type.  
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Figure 27: Dose-dependent dilation on addition of increasing doses of A76 in both BkCa 
wild type and knockout vessels 
A76 induced a dose-dependent dilation and drop of Fura ratio in both BkCa wild type and 
knockout vessels. The dose-dependent dilation to A76 was significantly increased in the BkCa-
knockouts (n=4) compared to the wild type (n=4), while there was no difference in the change of 
Fura ratio. (***<0,001) Two-Way Anova 
4.2.4.4.2. Influence on SERCA-dependent Calcium Control 
In addition to the treatment with IbTx, both α1 and α2 vessels were pre-treated with TG 
(1 μM).  
In α1 knockout vessels incubated with TG, there was less dilation but no difference in 
the decrease of the Fura ratio on addition of A76 at 100 μm A76  
(KO100 μM: +3.3 ± 1.0%, Fura ratio: -16.8 ± 1.2%) than in the equally treated wild type 
vessels (WT100 μM: +11.8 ± 0.8%; Fura ratio: -18.6 ± 2.3). 
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Figure 28: Effect of thapsigargin (TG) on A76 (100 μM)-induced dilation and decrease of 
Fura ratio in α1 knockout and wild type vessels 
A76-induced dilation was significantly decreased in α1 knockout vessels (n=11) compared to the 
wild type vessels (n=11) when the vessels were pre-treated with TG (1 μM). There was, 
however, no change in the Fura ratio in the α1 knockout vessels. (**<0,01) Two-Way Anova 
There was, however, no difference when pre-treating α2 wild type or knockout vessels 
with TG. Both wild type and knockout vessels dilated comparably  
(WTA76 100 μM: +11.0 ± 5.6%, KOA76 100 μM: +18.5 ± 7.1%), while there also was a similar 
decrease in the Fura ratio of both the α2 wild type and the knockout vessels  
(WTA76 100 μM: -34.8 ± 3.7%, KOA76 100 μM: -34.6 ± 2.7%). 
 
Figure 29: Effect of thapsigargin (TG) on A76 (100 μM)-induced dilation and decrease of 
Fura ratio in α2 knockout and wild type vessels 
There was no difference in A76-induced dilation or decrease in the Fura ratio (100 μM) in α2 
knockout (n=6) and wild type vessels (n=4) after incubation with TG (1 μM). Two-Way Anova 
 Influence on Calcium Sensitivity 
Ca2+ sensitivity in AMP-kinase’s α1 and α2 knockout vessels was analyzed by 
comparing the calcium-constriction relation in knockout animals and their respective 
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wild type controls using the experimental protocol already described above (see 
paragraph 4.2.3 Calcium Sensitivity).  
As in wild type vessels (see Figure 18 Effect of A76 on Ca2+ sensitivity), there was an 
upward shift, but no significant flattening of the graph in α2 knockout vessels on 
addition of A76 (100 μM). On addition of A76 there was only slightly less constriction 
even on the highest concentration of extracellular calcium (constriction without A76: 
from Ca2+ 0 mM: 184.0 ± 12.6 μm to Ca2+ 3 mM: 125.5 ± 16.0 μm; constriction with 
A76: from Ca2+ 0 mM: 184.3 ± 12.9 μm to Ca2+ 3 mM: 147.8 ± 16.8 μm), while the 
Fura ratio did not change (p=0.0533). There was consequently no sign of calcium 
desensitization seen in α2 knockout vessels. 
 
 
 
Figure 30: Effect of A76 on Ca2+ sensitivity in α2 knockout vessels 
A76-treated α2 knockout (n=4) vessels showed no significant decrease in constriction and no 
significant increase in the Fura ratio when exposed to increasing doses of extracellular Ca2+ 
(0.5 mM, 1 mM, 2 mM, 3 mM) and A76 (100 μM). Non-linear regression analysis  
A significant upward shift of the constriction values could, however, still be observed in 
both α1 wild type and knockout vessels treated with A76 (100 μM). Whereby both wild 
type and knockout vessels presented with comparable Fura ratio levels before and 
after the addition of A76 (KO without A76: from Ca2+ 0 mM: 0.7 ± 0.02 to 3 mM Ca2+: 
1.1 ± 0.03; KO with A76: from Ca2+ 0 mM: 0.8 ± 0.07 to 3 mM Ca2+: 1.1 ± 0.1; WT 
without A76: from 0 mM Ca2+: 0.68 ± 0.04 to 3 mM Ca2+: 0.98 ± 0.05; WT with A76: 
from 0 mM Ca2+: 0.62 ± 0.06 to Ca2+ 3 mM: 0.9 ± 0.12), they both constricted 
significantly less (pKO/WT=0.0001) to all levels of extracellular calcium (0.5–3  mM) 
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when treated with A76 (KO without A76: from 0 mM Ca2+: 185.0 ± 8.4 μm to 3 mM 
Ca2+: 116.3 ± 11.8 μm; KO with A76 0 mM Ca2+: 187.8 ± 8.1 μm to 3 mM Ca2+: 164.5 
± 15.3 μm; WT without A76: from Ca2+ 0 mM: 185.0 ± 8.4 μm to Ca2+ 3 mM: 116.3 ± 
11.8 μm; WT with A76: from Ca2+ 0 mM: 187.8 ± 8.1 μm to Ca2+ 3 mM: 164.5 ± 
15.3 μm).  
 
  
 
Figure 31: Effect of A76 on Ca2+ sensitivity in α1 wild type and knockout vessels 
Both A76-treated α1 wild type (n=6) and knockout (n=4) vessels showed less constriction despite 
comparable levels of the Fura ratio, when treated with increasing doses of extracellular Ca2+ 
(0.5 mM, 1 mM, 2 mM, 3 mM) and A76 (100 μM). (***<0.001) Non-linear regression analysis 
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5. Discussion 
5.1. Findings 
This thesis provides evidence that AMP-kinase activation induces a significant 
vasodilation in both mesenteric and skeletal muscle arteries of mice. The mechanisms 
leading to this vasodilation were shown to be the same ones that our group had 
already described in hamster vessels (Schneider, Schubert et al. 2015). As 
mesenteric arteries were shown to be well suited to analyze the effects of the AMP-
kinase on basal vascular tone and simultaneously on the vessels’ intracellular calcium 
levels, they could be used to further analyze the impact of the AMP-kinase’s subunits 
using genetically modified mice. This thesis focused on the importance of the two 
catalytic α subunits (α1 and α2) for vasodilation. It could be shown that the two AMP-
kinase activators A76 and PT1 dilate via the two α subunits, but predominantly via the 
α2 subunit. Most importantly, it could also be shown that the α2 subunit is essential for 
inducing calcium sensitivity.  
5.2. Characterization of Mouse Arteries  
Isolated arteries prove to be a good match to analyze the effect of the AMP-kinase as 
they contain in situ cells, which are important for vascular function but lack the 
biochemical complexity of a blood perfused living organ that would be present when 
studying small blood vessels in vivo. They thus facilitate the interpretation of the 
results, as there is less interference with the vascular pathway that is studied. It should 
be noted that to determine physiological relevance, in vivo experiments are to be 
carried out at a later stage. (Kreutz (2013)) 
All of our group’s former experiments addressed hamster femoral skeletal muscle 
arteries, where it could be shown that AMP-kinase’s activation induces substantial 
vasodilation in a calcium-dependent and calcium-independent manner. However, due 
to the lack of specific activators, it was hardly possible to study the contribution of the 
single subunits of the heterotrimeric AMPK enzyme. To further evaluate the 
importance of the AMP-kinase’s subunits in this thesis, it was necessary to switch to 
mouse arteries, as gene targeting tools for hamsters are much rarer and less 
established than mouse knockout models (Fan, Li et al. (2014)). The AMP-kinase’s 
impact on mouse vessels had, until our studies were performed, mainly been 
analyzed in larger arteries including the aorta, where AMP-kinase’s activation can 
induce vasodilation in an endothelium-dependent way by activating the eNOS and in 
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an endothelium-independent way (Cacicedo, Gauthier et al. (2011); Goirand, Solar et 
al. (2007)). Analyses of small resistance arteries, however, were missing.  
Our experiments with mouse femoral skeletal muscle arteries showed no differences 
to the previously analyzed hamster vessels. Due to skeletal muscle arteries only 
delivering very little material for future Western Blot analysis, another vessel type was 
sought. Mouse mesenteric arteries had long been used for vascular studies and 
because they presented much more material for the aforementioned Western Blots, it 
was decided to switch from hamster skeletal muscle arteries to mouse mesenteric 
arteries. 
Due to this change in vessel type, the differences and commonalities of these two 
vessel types concerning their vasoconstrictive and vasodilative reactivity had to be 
evaluated. While my experiments showed that there is no relevant difference in vessel 
constriction to U46, there appears to be less change in the Fura ratio (reflecting 
smooth muscle intracellular free calcium) in mesenteric arteries. As there is no 
significant difference in the raw Fura signal data, which could explain the increased 
ratio of the skeletal muscle arteries, the mesenteric arteries seem to be more calcium 
sensitive than skeletal muscle arteries. This would have to be investigated further. 
Acetylcholine seems to disappear more quickly in mesenteric as compared to skeletal 
muscle arteries, leading to a decreased endothelial reactivity to increasing doses of 
acetylcholine in mesenteric arteries, despite there being a good dilation induced by a 
single dose of acetylcholine (15 µM). The reason for this remains unclear. There are 
several possible explanations for this phenomenon that are further explained below.  
Mesenteric arteries might present with fewer M3 receptors compared to skeletal 
muscle arteries, but this would not explain the comparable dilation to a single dose of 
acetylcholine. The M3 receptors in mesenteric arteries could, however, also be 
desensitized when adding increasing doses of ACh, a phenomenon that has already 
been described in various other cell types (Tobin, Lambert et al. (1992); Willets, 
Challiss et al. (2001)).  
Interference with adipokines from mesenteric fatty tissue might also explain the better 
dilation of skeletal muscle arteries, which are not surrounded by fatty tissue. While 
there seems to be an interaction between perivascular adipose tissue (PVAT) and the 
eNOs via Cav-1, which blocks the eNOS and has been described in larger 
conductance vessels, PVAT is said to not influence acetylcholine-induced dilation of 
resistance arteries (Lee, Chen et al. (2014); Marchesi, Ebrahimian et al. (2009)). 
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Additionally, resistance arteries are small arteries where vasodilation is also more 
regulated via EDHF than eNOS (Bolz, de Wit et al. (1999); Shimokawa, Yasutake et 
al. (1996)). The PVAT’s influence on the eNOS consequently seems to be of minor 
importance for the vessels that were analyzed in this thesis. 
As mentioned by Li, Andersen et al. (2013), there can also be less dilation to 
increasing doses of acetylcholine in rat mesenteric arteries when PVAT is still 
attached to these arteries. In my setup, however, PVAT was completely removed, so 
that mechanically impaired diffusion of the vasodilators cannot explain the findings. 
The difference might also result from an augmented mesenteric endothelial death 
during the Fura incubation period of two hours. If the mesenteric endothelium is more 
susceptible to cellular death than its skeletal muscle counterpart, it would also explain 
the comparable reaction to the single dose of acetylcholine, as this was administered 
before the vessels were incubated with Fura-2. This is, however, also rather unlikely, 
as other experiments show that ACh is a very potent vasodilator, which only needs a 
relatively small number of endothelial cells to induce vasodilation. 
While there was a huge difference in endothelial reactivity, endothelial-independent 
relaxation induced by the L-type Ca2+ channel blocker nifedipine was comparable 
between skeletal muscle and mesenteric arteries. As nifedipine was added at the very 
end of the experiment and as the analysis had to be made comparing the effect of 
nifedipine to the initial constriction induced by norepinephrine, the reaction to 
nifedipine might have been contaminated by the reactions to the increasing doses of 
acetylcholine, which were added initially. 
As this thesis aimed to analyze the endothelium-independent mechanisms of AMP-
kinase’s activation and due to them presenting more material for further molecular 
studies, all AMP-kinase experiments were performed on mesenteric arteries.  
5.3. The AMP-Kinase in Mouse Mesenteric Arteries 
As already described in Section 1.2.2.2 Pathophysiological Relevance of the AMP-
Kinase, both catalytic AMPK α subunits have been described to have different effects 
on the AMP-kinase’s metabolic importance. While the lack of the α2 subunit severely 
influences glucose homeostasis, leading to glucose intolerance and insulin resistance 
and resulting in an elevated blood pressure, the knockout of the α1 subunit impairs the 
cell’s reactivity to oxidative stress leading to a shortened erythrocyte life span, anemia 
and splenomegaly (Wang, Liang et al. (2011); Viollet, Andreelli et al. (2003); Foretz, 
Hebrard et al. (2011); Wang, Dale et al. (2010)).  
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As described by Rubin, Magliola et al. (2005) the AMP-kinase’s α1 subunit is 
predominant in vascular smooth muscle cells of large arteries like the aorta. There 
was, however, not yet any indication about which catalytic α subunit and consequently 
which of the AMPK isomers would be of more dilatory importance in resistance 
arteries. The knockout experiments performed in this thesis aimed to further analyze 
this aspect. However, it is important to know that knockout animals can potentially 
adapt to the knockout of the respective gene. The result might thus not always be 
equivalent to the one gene being knocked out, but it could also reflect the organism’s 
adaptive reaction. It is also important to note that the AMP-kinase’s global double 
knockout, the knockout of both the α1 and the α2 gene, is not viable, so that only 
global single knockouts were analyzed (Viollet, Athea et al. (2009); Fu, Zhao et al. 
(2013)).  
It could be shown that all underlying genes for the AMP-kinases subunits except the 
Prkag3 gene, expressing the γ3 subunit, were present in the mouse mesenteric 
arteries used in this thesis. 
Both AMP-kinase activators that were used in this thesis, A76 and PT1, dilate blood 
vessels via an endothelial-independent way by activating the smooth muscle cell’s 
AMP-kinase (Schneider, Schubert et al. (2015)). These studies did not reveal any 
major endothelium-dependent vasodilatory component in the small vessels that were 
studied. Nevertheless, as several studies have described an endothelial AMP-kinase 
component that phosphorylates and thus activates the eNOS, L-NAME was used to 
inhibit a potential endothelial effect (Chen, Peng et al. (2009); Chen, Montagnani et al. 
(2003); Ford, Teschke et al. (2012)). The AMP-kinase activator A76 is reported to 
activate the AMP-kinase by binding to the β1 subunit, while PT1 is reported to activate 
the AMP-kinase by binding to the α1 subunit (Scott, van Denderen et al. (2008); Pang, 
Zhang et al. (2008)). The well-known AMPK activator AICAR for example is also 
reported to activate the AMP-kinase via the α1 subunit (Goirand, Solar et al. (2007)). 
Especially with PT1, which is considered to bind to the α1 subunit, one would expect 
this subunit to be of major importance for the dilation induced by the AMP-kinase. It 
was thus surprising that the vasodilation was not impaired in α1 knockout vessels. In 
α2 knockout vessels no difference between the knockout and the wild type vessels 
could be seen on addition of PT1. This second effect can be explained more easily as 
the α1 subunit, to which PT1 binds, would be able to take over for the knocked out α2 
subunit. The results from the α1 knockouts indicate a major importance for the 
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activation of PT1 via the α2 subunit. This implies that PT1 presumably influences the 
AMP-kinase via further binding sites in addition to its known binding site at the α1 
subunit. This has also been demonstrated by Pang, Zhang et al. (2008).  
There may also be a compensatory upregulation of the AMP-kinase’s α2 subunit 
and/or its respective dilatory mechanism covering for the loss of the AMP-kinase’s α1 
subunit. This also seems to be the case in the α2 knockout vessels, as one would 
expect at least a slight decrease in vasodilation when the α1 subunit, which is the main 
subunit in smooth muscle cells, is the only subunit inducing vasodilation (Rubin, 
Magliola et al. (2005)). 
 
As seen with PT1, the experiments with the other AMP-kinase activator A76 show 
similar results. The vasodilation elicited by them is not negatively influenced by the 
knockout of one of the subunits and there even is an increased dilation in the α1 
knockout vessels when adding A76. This implies that A76, just like PT1, appears to 
have different AMP-kinase target sites. A76 seemed to preferably activate the AMP-
kinase via its α2 subunit. However, it could also activate the AMP-kinase via the α1 
subunit even if less effectively. This was also observed by Xiao, Sanders et al. (2013). 
However, as with PT1, there seemed to be an efficient compensatory upregulation of 
the existing α subunit or its vasodilating mechanism, when the significant other subunit 
was knocked out.  
A compensatory upregulation of the still existent α subunit has until now also been 
described in the gastrocnemius and soleus muscle (Jorgensen, Treebak et al. (2007); 
Jorgensen, Viollet et al. (2004)). 
 
Both A76 and PT1 could also activate some other AMPK-independent vasodilative 
mechanism in a non-specific way. However, both activators, which are structurally 
unrelated, showed the same kind of reaction and as many studies have proven a 
direct AMP-kinase activation without presenting any relevant alternative dilatory 
mechanisms (except A76’s AMP-kinase-independent inhibitory influence on the 
Na+/K+-ATPase) this seems highly unlikely (Benziane, Bjornholm et al. (2009); Pang, 
Zhang et al. (2008); Scott, van Denderen et al. (2008)). 
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 The Effect of the AMP-Kinase’s α Subunits on Decreasing Intracellular 
Calcium Levels  
As mentioned in Section 1.1.2 Regulation of Vascular Tone, there are two 
mechanisms to induce vasodilation, the calcium-dependent and the calcium-
independent mechanism, also called calcium desensitization. Both of these 
mechanisms are influenced by the AMP-kinase activity with calcium desensitization 
being discussed later in this chapter (Wang, Liang et al. (2011)). Vasodilation via the 
calcium-dependent mechanism has in other vessels been shown to involve calcium-
decreasing mechanisms, one of which is SERCA activation, which induces a calcium 
uptake from the cytoplasm into its stores. Calcium that is removed by SERCA can 
consequently no longer be used to augment calmodulin-mediated MLCK activity and 
induce vasoconstriction (Brini and Carafoli (2009)). As shown by Schneider, Schubert 
et al. (2015), the AMP-kinase decreases intracellular calcium levels by activating 
SERCA via phosphorylation of phospholamban. While non phosphorylated 
phospholamban inhibits SERCA activity, the phosphorylated version allows for an 
enhanced SERCA activity (Jackson and Colyer (1996)). 
Another possibility to decrease the level of intracellular calcium and thus induce 
dilation in smooth muscle is by blocking the influx through voltage gated calcium 
channels via hyperpolarization. The BkCa-channel is a calcium-dependent potassium 
channel that induces hyperpolarization and consequently vasodilation on activation. It 
has been shown that the AMP-kinase could activate these channels in both mice and 
hamsters (Foller, Jaumann et al. (2012); Schneider, Schubert et al. (2015)).  
As these experiments showed a tendency that the two calcium-dependent vasodilative 
mechanisms might be attributed to one of the two AMPK α subunits, further 
experiments were conducted to verify this assumption. Only vessels from α1 knockout 
animals were sensitive to a SERCA blockade by its specific inhibitor thapsigargin. α1 
knockout vessels that were treated according to this protocol showed less dilation and 
a tendency towards a decrease of the Fura ratio at least when applying the highest 
dose of A76 (100 μM). This is consistent with the interpretation that the (remaining) α2 
subunit is interfering with the intracellular calcium levels via SERCA activation. In 
contrast α2 knockout vessels did not present with any differences compared to the wild 
type vessels when treated the same way. It must be noted that thapsigargin itself 
induced an almost complete vasodilation after 8-10 minutes. As this would interfere 
over time with obtaining a concentration response curve, only one concentration of 
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A76 could be used. In order to analyze the biggest effect, the highest dose of A76 that 
was used in the dose-response curves of 100 μM was chosen for these experiments. 
The other calcium decreasing mechanism was tested by pre-treating vessels with the 
BkCa-channel blocker iberiotoxin. There was slightly less dilation in the α2 knockout 
vessels when blocking the BkCa-channels. As this decrease in dilation could not be 
seen in the α1 knockouts, it is tempting to speculate that the AMPK α1 subunit 
predominantly induced vasodilation via BkCa-channel activation. 
However, since there were only slight differences with respect to the dose-response 
curves, one has to assume that strong compensatory mechanisms hid clearer 
knockout effects of either subunit. Other experiments performed in our laboratory have 
indeed shown that only the combined inhibition of SERCA and the BkCa-channels 
could severely reduce the AMPK-induced dilation (Schneider, Schubert et al. (2015)). 
Another possibility is a potential compensatory increase of the remaining α subunit 
after the knockout of either the α1 or the α2 subunit. It has been shown in skeletal 
muscle that the expression of the remaining subunit can be upregulated (Jorgensen, 
Viollet et al. (2004); Jorgensen, Treebak et al. (2007)). We did not test this possibility 
in more detail.  
For further analysis, BkCa knockout vessels should be tested with thapsigargin to 
verify that there is no longer an effect on A76 induced dilation, as both dilatory 
mechanisms would not be functional in this setting and a complete knockout would 
have been generated. 
 The Effect of the AMP-Kinase’s α Subunits on Calcium Sensitivity 
Calcium sensitivity is the other important mechanism in addition to the receptor-
mediated increase or decrease of intracellular calcium for regulating vascular tone. 
Compared to the receptor-mediated regulatory mechanism, which affects vascular 
tone instantly, calcium desensitization takes effect with a delay of approximately five 
minutes.  
Calcium sensitivity is regulated by both the MLCP and the MLCK and their respective 
activation or inhibition. The AMP-kinase does not influence the MLC directly, but is 
reported to influence both the MLCP, the MLCK and actin to induce calcium 
desensitization and consequently vasodilation in larger conductance and small 
resistance arteries (Bultot, Horman et al. (2009); Horman, Morel et al. (2008); Wang, 
Liang et al. (2011); Schubert, Qiu et al. (2017)).  
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In mouse vessels it could be shown that the AMP-kinase activates the MLCP by 
blocking the RhoA/ROCK/MYPT1 pathway, which would otherwise block the MLCP, 
via p190-GAP (Wang, Liang et al. (2011)).  
The AMP-kinase has, however, not only been described to take part in calcium 
desensitization via blocking the inhibition of the MLCP but it has also been reported to 
block the MLCK directly via phosphorylation at Ser815 (Horman, Morel et al. (2008)). 
There is only scarce evidence concerning which AMPK α subunit is responsible for 
inducing this delayed dilation, with Wang, Liang et al. (2011) describing an influence 
of the α2 subunit for this in the aorta. To date there is no evidence for the influence of 
both AMPK subunits on calcium sensitivity in resistance arteries.  
These mechanisms were not found to play a role in other experiments performed in 
our lab. Rather, the AMP-kinase influenced vascular tone in a calcium independent 
manner by actin-depolymerization. It could be shown by Schubert, Qiu et al. (2017) 
that the AMP-kinase dephosphorylates cofilin, which influences actin thickness and 
ramification and induces depolymerization of F-actin, thus leading to vasodilation. 
My experiments were not meant to further analyze the influence of the AMP-kinase on 
the different mechanisms influencing calcium sensitivity but focused on the relative 
roles of the AMP-kinase’s α subunits.  
I could show that A76 induced calcium desensitization in ordinary mesenteric arteries. 
By firstly pre-treating the vessels with calcium-free MOPS and then with a calcium-free 
MOPS with an elevated potassium (K+ 125 mM), it was ensured that both the vessels’ 
intracellular calcium stores and the extracellular calcium level was down to zero and 
the voltage-dependent calcium channels (VDCCs) were opened. By opening the 
voltage-dependent calcium channels a change in the extracellular calcium levels led 
to a corresponding change in intracellular calcium levels. A76 reduced 
vasoconstriction to the increasing calcium concentrations compared to a pre-test that 
presented with the same intracellular calcium levels but without the AMP-kinase 
activator. These experiments could not be performed with PT1 as it interfered with the 
calcium measurement.  
To further evaluate which α subunit has a major influence on calcium sensitivity, 
experiments were consequently conducted in the respective AMP-kinase’s subunit 
knockout mice. Due to bleaching artefacts of Fura, which can occur in long term 
experiments such as these, absolute as opposed to relative values were analyzed. 
Using these absolute values, however, usually makes the resulting evaluation more 
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susceptible to vessel-related characteristics such as different original Fura loading, but 
as vessel characteristics were comparable to the baseline in each experiment and due 
to heavy bleaching artefacts that interfered with the analysis, absolute values still 
provided the more reliable data. As in wild type vessels, A76 impaired the 
vasoconstriction induced by increasing doses of extracellular Ca2+, thus inducing 
calcium desensitization in α1 knockout vessels. Adding A76 did, however, not lead to 
decreased vasoconstriction and thus calcium desensitization in α2 knockout vessels. 
Due to these experiments, the AMP-kinase’s α2 subunit seems to control calcium 
sensitivity. This is an important new function of the α2 subunit and potentially offers a 
new specific target for vasoactive medication, especially when Ca2+-entry blockers are 
not effective.  
This study, however, has not yet analyzed whether this α2 subunit-mediated effect 
works through actin depolymerization.  
5.4. Consequences of these Findings for Vascular Control  
Basal vascular tone is of major importance in regulating tissue perfusion by adapting 
vascular resistance (Jackson (2000)). Basal vascular tone in resistance arteries is 
mainly defined by myogenic tone, which provides a baseline constriction, upon which 
further stimuli including vasoconstrictors or endothelium dependent factors like eNOS 
and EDHF can influence the basal vascular tone (Vallance (1992); Shimokawa, 
Yasutake et al. (1996); Tykocki, Boerman et al. (2017)). Numerous ion channels 
influencing the membrane potential play an important role in setting the myogenic tone 
(Tykocki, Boerman et al. (2017)). 
Regarding literature findings, the activated AMP-kinase is considered to decrease 
basal vascular tone by phosphorylating the eNOS, consequently inhibiting the 
phosphorylation of the MLC via the RhoA/ROCK/MYPT1 pathway (Chen, Peng et al. 
(2009); Chen, Montagnani et al. (2003); Ford, Teschke et al. (2012); Wang et al. 
2011). In my experiments both the α1 and the α2 knockouts present with no significant 
basal tone, but appear to be completely relaxed, which agrees with our earlier findings 
of a lack of endothelial AMP-kinase induced dilation.  
On the other hand, the AMP-kinase and its two catalytic subunits are said to influence 
vascular tone by inhibiting vasoconstriction (Wang, Liang et al. (2011); Horman, Morel 
et al. (2008); Gayard, Guilluy et al. (2011)). Wang, Liang et al. (2011) and Gayard, 
Guilluy et al. (2011) showed that the AMP-kinase inhibits the RhoA/ROCK/MYPT1 
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pathway via phosphorylation of serine of p190-GAP or Ser188 and thus activates the 
MLCP, leading to a vasodilation.  
In my experiments, the AMPK α2 subunit significantly decreased vasoconstriction to 
norepinephrine (also seen in Wang, Liang et al. (2011)), while at the same time not 
significantly influencing the Fura ratio, which thus further implies that the AMPK α2 
subunit decreases calcium sensitivity (as already pointed out in Chapter 5.3.2). As 
vasoconstriction and vasodilation lead to changes in blood pressure, the increased 
constriction observed in α2 knockout mice compared to the control mice can also 
explain the increased blood pressure observed in α2 knockout mice by Wang, Liang et 
al. (2011). Reducing blood pressure by activating the AMP-kinase would thus be an 
interesting mechanism for hypertensive patients. Due to the AMP-kinase’s metabolic 
effects it would be of even greater importance for patients suffering from the metabolic 
syndrome. The well-known antidiabetic drug Metformin, which has been described to 
lower blood glucose via AMP-kinase activation, could thus be seen as a potential 
antihypertensive drug (Zhou, Myers et al. (2001). It has, however, been described to 
have no significant effect on blood pressure in diabetic and non-diabetic humans 
(Snorgaard, Kober et al. (1997); Wulffele, Kooy et al. (2004)). In recent years 
Metformin has also been described to lower blood glucose in an AMP-kinase 
independent manner (Rena, Hardie et al. (2017). This and the lack of influence on 
vascular tone show that the effect mechanisms of Metformin have not yet been 
completely understood. 
In contrast to what would be expected from literature and from the α2 experiments, 
there was no difference in constriction to norepinephrine in α1 wild type and knockout 
vessels (Wang, Liang et al. (2011); Horman, Morel et al. (2008)). In addition to this 
non-existent difference in constriction to norepinephrine in the α1 knockout, there was 
no difference for both α1 and α2 wild type and knockout vessels concerning 
constriction to K+ 125 mM. Horman, Morel et al. (2008) reported less constriction in 
wild type than in α1 knockout mice on addition of K+ 100 mM, which is an indication 
that the AMP-kinase might not only influence the MLCP but also block the MLCK. As 
mentioned earlier Horman, Morel et al. (2008) used aortic rings and thus conductance 
vessels, where the AMP-kinase could influence vascular tone in a subunit 
independent fashion and where it might present with this additional effect on the 
MLCK. This has until now not been further evaluated in additional studies.  
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This study focused on the pharmacological stimuli of the AMP-kinase. The AMP-
kinase is, however, also activated by physiological stimuli like hypoxia, fasting or 
physical exercise that increase ATP consumption inducing an increase in the 
AMP/ATP ratio (Hardie, Carling et al. 1998); Hardie and Lin (2017)). As these stimuli 
are, however, more difficult to quantitatively measure, it was decided to focus on a 
pharmacological stimulation. 
To further analyze the importance and the effects of the AMP-kinase 
pharmacologically blocking the AMP-kinase would also be an option as the double 
knockout is not viable. Unfortunately, the most potent inhibitor of the AMP-kinase, 
compound C, has been described as unselective, so that this method was not used in 
this study (Bain, Plater et al. (2007). 
A good alternative would have been inducible, smooth muscle specific AMPK 
knockout mice for both α subunits, but these mice were not yet available at the time of 
my experiments.  
6 Summary 
A 
6. Summary 
The heterotrimeric AMP-kinase is an enzyme which is nearly ubiquitously expressed. 
It was originally considered to play a role in the liver and muscle metabolism but there 
is increasing evidence that it also plays a role in the control of vascular functions. To 
further examine the effects of the AMP-kinase and its subunits on vascular tone, it 
was important to switch from a hamster model to a mouse model, as a hamster 
knockout model was not available. In this thesis, it was therefore determined whether 
mouse arteries present with a similar AMP-kinase induced regulation of the vascular 
tone compared to the hamster skeletal muscle arteries previously used in our group. It 
was further analyzed whether this influence on the vascular tone can be seen in 
different vascular beds, such as the vascular beds of mesenteric and skeletal muscle 
arteries. Studies of knockout animals were subsequently conducted to determine 
whether the two alternative AMP-kinase α subunits played any specific role in the 
regulation of the vascular tone of small murine arteries.  
All experiments were carried out using freshly isolated vessels that were kept under 
constant pressure. Changes in vascular diameter were studied by a video-based 
approach, whereas the intracellular free calcium in the vascular smooth muscle was 
measured using the Fura-2 technique. The AMP-kinase, which is stimulated by 
hypoxia, fasting or physical exercise in vivo, was studied here using two structurally 
different pharmacologic stimulators, A769662 and PT1.  
Western Blot analyses to analyze the signaling processes, which are beyond the 
scope of this thesis, require sufficient quantities of vessel-derived protein. It was 
therefore decided to focus mainly on mesenteric arteries as the mesenteric vascular 
bed provides ample material compared to the limited number of accessible skeletal 
muscle arteries in the mouse. Our analysis of the two different vascular beds showed 
that both exhibited a marked endothelium-dependent dilation in response to 
acetylcholine after preconstriction with the thromboxane analogue U46619. The 
acetylcholine-induced response, however, faded quickly in mesenteric arteries but not 
in skeletal muscle arteries. This was probably due to M3 receptor desensitization or a 
potential adipokine interference. 
As the AMP-kinase’s effects were studied with reference to the vascular smooth 
muscle, this aspect was not studied further. It could be shown that all isoforms of the 
three AMP-kinase subunits (α, β, γ) were expressed in the mesenteric arteries, except 
the γ3 subunit. In mesenteric arteries both catalytic subunits (α1 and α2) were present 
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but the α1 subunit was expressed at a higher level than the α2 subunit. Both AMP-
kinase activators (A76 and PT1) led to a dose-dependent dilation and A76 also 
resulted in a concentration-dependent decrease of the smooth muscles’ free calcium 
concentration (as measured by the Fura ratio) in mesenteric arteries. Earlier studies 
with hamster vessels by our lab revealed that the decrease in calcium is due to 
SERCA and BkCa-channel activation. The silencing of one of the α subunits only 
exerted minor effects on the overall dilatory response of the vessels to the AMP-
kinase stimulation. This surprisingly little influence of either the α1 or the α2 knockout 
on the overall dilation suggests that even if a specific effect of the subunits for one of 
these calcium-decreasing mechanisms existed, it was probably hidden by a mutual 
compensation of the calcium decreasing effects of BkCa channel and SERCA 
activation. However, further experiments with the SERCA blocker thapsigargin 
showed that only vessels from α1 knockout mice were sensitive to SERCA inhibition, 
suggesting that the AMPK α2 subunit induces vasodilation and a decrease in the 
intracellular calcium levels by mainly activating SERCA, which in turn would be 
consistent with the predominant activation of BkCa-channels by the AMPK α1 subunit. 
In functionally calcium-permeabilized vessels, stimulation of the AMP-kinase reduced 
the contractile response of the arteries to increasing calcium concentrations, which is 
defined as calcium desensitization of the smooth muscle. This mechanism could also 
be observed in intact vessels since murine mesenteric arteries could in appropriate 
conditions dilate without changes in intracellular calcium levels. This calcium-
independent dilatory mechanism, was also analyzed for the influence of the AMP-
kinase and its subunits. We could demonstrate that the calcium-independent 
vasodilation is primarily regulated by the AMP-kinase’s α2 subunit, without evident 
compensation by the α1 subunit, thus offering a potential new target for vasoactive 
medication. This study has, however, not further analyzed the mechanisms underlying 
this calcium desensitization.  
Due to the AMP-kinase’s metabolic and vasoregulating effects for patients presenting 
with the metabolic syndrome for instance, these findings can offer further 
understanding for potential medication that targets metabolic and vascular effects at 
the same time. To further investigate the physiological impact of these findings, 
experiments with in vivo models and inducible, smooth muscle specific AMPK double 
knockout mice, which were not yet available at the time of my experiments, should be 
conducted.  
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7. Zusammenfassung 
Die heterotrimere AMP-Kinase ist ein beinahe ubiquitär exprimiertes Enzym, von dem 
ursprünglich ausgegangen war, dass es eine wichtige Rolle im Leber- und 
Muskelstoffwechsel spielt. Es gibt jedoch zunehmend Hinweise darauf, dass die AMP-
Kinase auch in der Kontrolle der Gefäßfunktion eine Rolle spielt. Um die Effekte der 
AMP-Kinase und ihrer Untereinheiten weiter zu untersuchen, war es wichtig von 
einem Hamster- auf ein Mausmodel zu wechseln, da Hamsterknockoutmodelle nicht 
existierten. In dieser Doktorarbeit wurde daher zuerst untersucht, ob Mausarterien, im 
Vergleich zu den zuvor in unserer Arbeitsgruppe verwendeten 
Hamsterskelettmuskelarterien, eine ähnliche AMP-Kinase-induzierte Regulation des 
Gefäßtonus zeigten. Weiterhin wurde untersucht, ob dieser Einfluss auf den 
Gefäßtonus in verschiedenen Gefäßbetten, wie zum Beispiel den Gefäßbetten der 
Mesenterial- und der Skelettmuskelarterien, gesehen werden kann. Im Anschluss 
daran wurden Versuche an Knockouttieren durchgeführt, um festzustellen, ob die zwei 
alternativen AMPK α Untereinheiten eine spezifische Rolle in der Regulation des 
Gefäßtonus der kleinen Mausarterien spielen. 
Alle Experimente wurden an frisch isolierten Gefäßen durchgeführt, die unter einem 
konstanten Druck gehalten wurden. Änderungen des Gefäßdurchmessers wurden 
videographisch registriert, während das freie intrazelluläre Calcium in den glatten 
Gefäßmuskelzellen mit Hilfe der Fura-2 Technik gemessen wurde. 
Die AMP-Kinase, die unter anderem durch Hypoxie, Fasten oder sportliche Aktivität in 
vivo stimuliert wird, wurde hier mit Hilfe von zwei strukturell unterschiedlichen 
pharmakologischen Stimulatoren, A769662 and PT1, untersucht.  
Da die Western Blotanalysen, als Mittel zur über diese Doktorarbeit hinausgehenden 
Analyse zellulärer Signalwege, ausreichende Mengen an Protein aus den Gefäßen 
benötigen, wurde beschlossen den Fokus auf die Mesenterialgefäße zu legen, da das 
mesenteriale Gefäßbett, verglichen mit der begrenzten Anzahl zugänglicher 
Skelettmuskelarterien in der Maus, ausreichend Gefäßmaterial liefern kann. 
Unsere Analyse der beiden verschiedenen Gefäßbetten zeigte, dass die Gefäße 
dieser beiden Gefäßbetten nach einer Vorkontraktion mit dem Thromboxananalogon 
U46619 eine starke Endothel-abhängige Dilatation auf Acetylcholin zeigten. Die durch 
Acetylcholin induzierte Vasodilatation ließ jedoch in den Mesenterialarterien, nicht 
aber in den Skelettmuskelarterien, schnell nach. Dies lag wahrscheinlich an einer 
Desensitivierung der M3-Rezeptoren oder einer potentiellen Interferenz durch 
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Adipokine. Da die Effekte der AMP-Kinase in Bezug auf den glatten Gefäßmuskel 
untersucht wurden, wurde dieser Aspekt jedoch nicht weiter untersucht.  
Es konnte gezeigt werden, dass alle Isoformen der drei AMP-Kinase Untereinheiten 
(α, β, γ) bis auf die γ3 Untereinheit in den Mesenterialarterien exprimiert waren. In den 
Mesenterialarterien waren beide katalytischen Untereinheiten (α1 und α2) vorhanden, 
die α1 Untereinheit war jedoch stärker exprimiert als die α2 Untereinheit. Beide AMPK-
Aktivatoren (A76 und PT1) induzierten eine dosisabhängige Vasodilatation, wobei A76 
auch einen konzentrationsabhängigen Abfall der intrazellulären freien 
Calciumkonzentration in den glatten Muskelzellen der Mesenterialgefäße induzierte. 
Unsere früheren Versuche an Hamstergefäßen hatten gezeigt, dass dieser 
Calciumabfall durch Aktivierung der SERCA und der BkCa-Kanäle entsteht. Der 
Knockout einer der zwei α Untereinheiten hatte nur einen geringen Effekt auf die 
durch die AMPK-Stimulation ausgelöste, gesamte vasodilatatorische Gefäßantwort. 
Dieser überraschend geringe Einfluss sowohl der α1 als auch der α2 Untereinheit auf 
die Gesamtdilatation suggeriert eine gegenseitige Kompensation der Calcium-
reduzierenden Effekte (der BkCa-Kanal und der SERCA Aktivierung), die einen 
eventuell existierenden spezifischen Effekt der α Untereinheiten auf einen dieser 
Calcium-reduzierenden Mechanismen maskiert.  
Weitere Experimente mit dem SERCA-Blocker Thapsigargin haben gezeigt, dass nur 
Gefäße von α1 Knockoutmäusen empfindlich für eine Hemmung der SERCA waren, 
was darauf hindeutet, dass die AMPK α2 Untereinheit hauptsächlich durch eine 
Aktivierung der SERCA eine Vasodilatation und einen Abfall der intrazellulären 
Calciumspiegel induziert. Dies wäre wiederum vereinbar mit der vorrangigen 
Aktivierung der BkCa-Kanäle durch die AMPK α1 Untereinheit. 
In funktionell Calcium-durchlässigen Gefäßen führte die Stimulation der AMP-Kinase 
zu einer reduzierten Gefäßkontraktion auf ansteigende Calciumkonzentrationen. Dies 
bezeichnet man als Calciumdesensitivierung des glatten Gefäßmuskels. Dieser 
Mechanismus konnte auch in intakten Mausgefäßen beobachtet werden, da die 
Mesenterialgefäße unter den richtigen Bedingungen ohne Änderung der 
intrazellulären Calciumspiegel dilatieren konnten. Dieser Calcium-unabhängige 
Dilatationsmechanismus wurde ebenfalls auf den Einfluss der AMP-Kinase und ihrer 
Untereinheiten analysiert. Wir konnten zeigen, dass die Calcium-unabhängige 
Vasodilatation vorrangig durch die AMPK α2 Untereinheit reguliert wird. Es zeigten 
sich keine Hinweise auf eine offensichtliche Kompensation durch die α1 Untereinheit, 
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sodass diese Regulation der Calciumdesensitivierung durch die α2 Untereinheit einen 
potentiellen neuen Angriffspunkt für vasoaktive Medikamente darstellt. Diese Arbeit 
beschäftigte sich jedoch nicht genauer mit den dieser Calciumdesensitivierung 
zugrunde liegenden Mechanismen.  
Aufgrund der metabolischen und gefäßregulierenden Effekte der AMP-Kinase für 
Patienten mit zum Beispiel dem metabolischen Syndrom können diese Erkenntnisse 
zu einem besseren Verständnis für potentielle neue Medikamente, die an 
metabolischen und vaskulären Effekten gleichzeitig angreifen, führen. Um die 
physiologische Bedeutung dieser Erkenntnisse weiter zu untersuchen, sollten 
Versuche an in vivo Modellen und induzierbaren glattmuskulären AMPK 
Doppelknockoutmäusen, die zur Zeit der Durchführung dieser Experimente noch nicht 
verfügbar waren, durchgeführt werden.  
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